
==== Front
J Transl Med
J Transl Med
Journal of Translational Medicine
1479-5876
BioMed Central London

39238004
5564
10.1186/s12967-024-05564-2
Review
The multifaceted role of the stroma in the healthy prostate and prostate cancer
http://orcid.org/0000-0001-7778-1042
Di Carlo Emma edicarlo@unich.it

12
Sorrentino Carlo 12
1 https://ror.org/00qjgza05 grid.412451.7 0000 0001 2181 4941 Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti- Pescara, Via dei Vestini, Chieti, 66100 Italy
2 https://ror.org/00qjgza05 grid.412451.7 0000 0001 2181 4941 Anatomic Pathology and Immuno-Oncology Unit, Center for Advanced Studies and Technology (CAST), “G. d’Annunzio” University of Chieti-Pescara, Via L. Polacchi 11, Chieti, 66100 Italy
5 9 2024
5 9 2024
2024
22 82512 4 2024
1 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Prostate cancer (PC) is an age-related disease and represents, after lung cancer, the second cause of cancer death in males worldwide. Mortality is due to the metastatic disease, which mainly involves the bones, lungs, and liver. In the last 20 years, the incidence of metastatic PC has increased in Western Countries, and a further increase is expected in the near future, due to the population ageing. Current treatment options, including state of the art cancer immunotherapy, need to be more effective to achieve long-term disease control. The most significant anatomical barrier to overcome to improve the effectiveness of current and newly designed drug strategies consists of the prostatic stroma, in particular the fibroblasts and the extracellular matrix, which are the most abundant components of both the normal and tumor prostatic microenvironment. By weaving a complex communication network with the glandular epithelium, the immune cells, the microbiota, the endothelium, and the nerves, in the healthy prostatic microenvironment, the fibroblasts and the extracellular matrix support organ development and homeostasis. However, during inflammation, ageing and prostate tumorigenesis, they undergo dramatic phenotypic and genotypic changes, which impact on tumor growth and progression and on the development of therapy resistance. Here, we focus on the characteristics and functions of the prostate associated fibroblasts and of the extracellular matrix in health and cancer. We emphasize their roles in shaping tumor behavior and the feasibility of manipulating and/or targeting these stromal components to overcome the limitations of current treatments and to improve precision medicine’s chances of success.

Keywords

Tumor microenvironment
Prostate cancer-associated fibroblasts
Extracellular matrix
Desmoplasia
Prostate cancer progression
Ageing population
http://dx.doi.org/10.13039/501100005010 Associazione Italiana per la Ricerca sul Cancro IG 2019 - ID. 23264 http://dx.doi.org/10.13039/501100021856 Ministero dell’Università e della Ricerca 2014–2020 (PON R&I) Sorrentino Carlo issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

The global burden of prostate cancer (PC) is substantial, ranking among the top five cancers for both incidence and mortality [1]. It is particularly common in developed Countries since, in addition to individual biological and genetic factors, environment and lifestyle impact the risk of developing the disease and surviving [2]. In the last 20 years the incidence of metastatic PC, which still lacks effective treatment, has increased in the U.S. from 11.58 cases per 100.000 men (4% of the total PC incidence) to 17.30 cases per 100.000 men (6% of the total PC incidence) [3], and an increase is expected due to the worldwide population aging. Improving the effectiveness of the therapeutic landscape, including the newly approved immunotherapies, for long-lasting control of advanced PC is a major challenge in urological oncology.

The histopathological architecture of the prostate, in which the stroma is widely represented, and plays an active role in tumorigenesis, raises the question whether targeting or manipulating stromal components, among which fibroblasts and the extracellular matrix (ECM) proteins predominate, would lead to a full response to current and developing therapies, including the recently approved autologous T cell vaccination (Sipuleucel-T) for the treatment of asymptomatic, or minimally symptomatic, metastatic castration-resistant (mCR) PC [4].

The prostatic stroma is the supportive tissue framework surrounding the glandular epithelium, which facilitates its function by supplying oxygen and nutrients, via blood vessels, and which regulates smooth muscle contraction during ejaculation, via sympathetic and parasympathetic nerve fibers [5]. Its cellular composition consists of fibroblasts embedded in the collagen and elastin rich extracellular matrix (ECM) they produce, which also contains smooth muscle cells, blood and lymphatic vessels, and nerves. The prostatic stroma harbors and regulates innate and adaptive immune cells, such as naive, tissue-resident memory and regulatory CD4+T cells, as well as cytotoxic and tissue-resident memory CD8+T-cells, CD16+ and CD16− NK cells, B cells, zinc transporter-expressing prostate-associated macrophages [6], mast cells and a paucity of immature, usually tolerogenic, dendritic cells [7]. All the stromal components are hormone sensitive and undergo substantial phenotypical and genotypical changes depending on aging, inflammation, and cancer, as discussed below.

Origin and functions of fibroblasts in the prostatic stroma

Prostatic stroma fibroblasts originate from several sources.

During embryonic development, mesenchymal progenitor cells migrate from the urogenital sinus mesenchyme (UGM) [8] to the developing prostate gland, and differentiate into different cell types, including fibroblasts, smooth muscle cells, and endothelial cells. The periprostatic mesenchyme surrounding the developing prostate also contributes to the pool of stromal fibroblasts. While the UGM induces prostatic epithelial development [9], signals from the developing glandular epithelium induce the mesenchymal cells of the surrounding tissue to differentiate into fibroblasts [8]. These mesenchymal-epithelial interactions are essential for prostate development. In addition to androgens, which regulate both epithelial and fibroblast proliferation and differentiation, trasforming growth factor beta (TGFβ) is a key regulator of epithelial-mesenchymal interactions during organogenesis. TGFβ signaling from the UGM regulates epithelial proliferation, differentiation, and apoptosis [10], and modulates androgen signaling, fine-tuning the response of epithelial cells to androgens.

In adult tissues, including the prostate gland, bone marrow-derived mesenchymal stem cells (MSCs) can migrate to sites of tissue injury or inflammation and differentiate into fibroblasts, under appropriate microenvironmental conditions [11, 12]. Once established in the prostatic stroma, resident fibroblasts can undergo local proliferation and differentiation to replenish the fibroblast population. This process contributes to the maintenance of fibroblast density and function within the prostate stroma.

Overall, fibroblasts of the prostatic stroma arise from multiple sources, including the embryonic mesenchyme, the periprostatic mesenchyme, bone marrow-derived MSCs, and from the proliferation and differentiation of resident fibroblasts. Resting fibroblasts resident in the normal prostate stroma, positively stain for vimentin and PDGFRα, and can be distinguished from other stromal cells by their surface expression of CD49a, CD49e, CD51/61, and CD30. They have been characterized into two phenotypically and functionally distinct subtypes, namely Sca-1+CD90+fibroblasts, which are located close to the epithelium and express growth factors and genes associated with developmental process and androgen-regulated epithelial cell survival, and Sca-1+CD90−/lowmyofibroblast-like cells, which highly express genes associated with the extracellular matrix and cytokine-mediated signaling pathways, indicating a role in tissue repair and immune responses [13].

Fibroblasts play key roles in the prostatic stroma.

1. Secretion of extracellular matrix (ECM) components such as collagen, elastin, and fibronectin, which form the framework providing structural support to the prostate tissue [14]. 2. Maintenance of tissue homeostasis by regulating the balance of cell proliferation and cell death within the prostate tissue. In response to injury or inflammation, fibroblasts become activated and convert into highly contractile myofibroblasts (MFBs), co-expressing vimentin and Alpha Smooth Muscle Actin (αSMA), which secrete ECM components, such as collagen type-I and type-III and are destined for apoptosis after promoting would healing [15]. They proliferate, migrate to the site of injury, and produce ECM components to facilitate tissue repair and restoration of normal tissue architecture. Fibroblasts and the ECM are key components of the stem cell niche and generate an interconnected network of signaling pathways, which allow epithelial stem cell survival and regulate the balance between self-renewal and differentiation, in both normal condition and following injury [16]. 3. Crosstalk with neighboring epithelial cells through the release of mediators that activate paracrine signaling pathways, such as tumor necrosis factor-alpha (TNFα), which exerts growth inhibitory effects on normal prostatic epithelia [17]. Prostatic stromal fibroblasts and epithelial cells engage in bidirectional communication. Fibroblasts secrete growth factors, such as basic fibroblast growth factor (FGF)/FGF-2, transforming growth factor-beta (TGFβ), insulin-like growth factors (IGFs) and keratinocyte growth factor (KGF), which can regulate epithelial cell proliferation and differentiation, and the release of ECM components, such as collagen and elastin, which sustain epithelial cells and maintain the overall architecture of the prostate gland. Conversely, epithelial cells produce AR-modulated growth factors, including TGFβ, IGF, FGF-2 and epidermal growth factor (EGF) [18], and signaling molecules, such as Wnt and Hedgehog proteins (e.g., Sonic hedgehog), which can drive fibroblasts towards a myofibroblast phenotype and up-regulate the expression of ECM components [19, 20]. Prostatic epithelia can also secrete enzymes, such as matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), to balance ECM degradation and remodeling. Stromal fibroblast-epithelial cell interactions are essential for the normal development, differentiation, and function of the glandular epithelium. 4. Immunomodulation and immune privilege maintenance. Through the production and release of cytokines, such as Interleukin-6 (IL-6), TNFα, TGFβ, IL-1β, IL-33, and CXC and CC chemokines [21–25], prostatic fibroblasts regulate immune cell recruitment and activity to the site of inflammation or infection, and mainly establish an immunosuppressive environment. IL-6 signaling inhibits the expression of MHC-II, CD80/86, and IL‐12 in dendritic cells (DCs) [26] and re‐programs the differentiation into IL‐10‐producing regulatory DCs [27], promotes differentiation into M2 macrophages [28] and hinders T‐cell mediated antitumor responses [29]. TNFα has demonstrated ambivalent functions, mediating both proinflammatory and paradoxical anti-inflammatory and immunomodulatory effects, such as inactivation of TCR signaling [30] or induction of T cell exhaustion [31], CD8+T cell killing and reduction of autoreactive T cells [32]. TNFα may also stimulate myeloid-derived suppressor cells (MDSCs) [33, 34] and may promote regulatory T cell (Treg) expansion and functions [35, 36]. IL-1β promotes the recruitment of immunosuppressive neutrophils, inhibits macrophage activation and accumulation of effector T cells [37]. IL-33 has revealed immunosuppressive functions by promoting M1 to M2 transition and inhibition of T lymphocyte-mediated tumor cell killing [38]. It also promotes a Th2 immune environment and potentiates the suppressive activity of Tregs [39].

Moreover, fibroblasts and stromal components may contribute to the immune privileged state of prostatic tissue, which exhibits limited immune responses compared to other tissues, by regulating the local immune environment and by suppressing excessive immune activation. In addition to creating a physical barrier that limit the infiltration of immune cells, stromal fibroblasts and smooth muscle cells can secrete immunosuppressive cytokines such as TGFβ and IL-10, which dampen the local immune response. TGFβ promotes the differentiation of naïve CD4+ T cells into Tregs, which are critical for maintaining immune tolerance and preventing autoimmune responses, it inhibits the proliferation and cytotoxic activity of CD8+ T cells and downregulates the maturation and antigen-presenting capacity of DCs [40]. IL-10 suppresses the production of pro-inflammatory cytokines, it promotes the development and function of Tregs, inhibits the expression of MHC class II and co-stimulatory molecules (CD80, CD86) on DCs and macrophages, and inhibits the differentiation and proliferation of T helper cells, particularly Th1 and Th17 cells, which are involved in pro-inflammatory responses [41]. Fibroblasts also can express co-inhibitory receptor ligands and checkpoints of T cell functions. Proinflammatory cytokine-induced expression of FasL on fibroblasts [42] might confer immune privilege by inducing apoptosis in infiltrating immune cells, thus suppressing the inflammatory response, and preventing autoimmune reaction, while favoring immune evasion by cancer cells [43, 44]. In response to IFNγ, stromal fibroblasts may express inhibitory PD-1 ligands, such as PD-L1 [45–47], that engage with immune checkpoints, further inhibiting immune activation [48], and can express Indoleamine 2,3-Dioxygenase (IDO). This tryptophan-catabolizing enzyme contributes to an immunosuppressive environment, by inhibiting T cell proliferation and by promoting Treg development, which favors tumor immune evasion [49, 50]. 5. Support of blood vessels and nerves by contributing to their maintenance and organization within the prostate stroma. Angiogenesis is crucial for wound healing and fibroblasts may produce angiogenic mediators such as VEGF, FGF-2, PDGF, TGFβ, and angiopoietins, such as Ang-1 and Ang-2, which regulate blood vessel formation and maturation. Fibroblasts can also produce interleukins (e.g., IL-8) [51] and chemokines (e.g., CXCL12 and CXCL5) [52–54] that contribute to angiogenesis by recruiting and activating endothelial cells and other cell types involved in the process [55]. Stromal fibroblasts also provide trophic support to nerve fibers and may produce several neurotrophic factors including Nerve Growth Factor (NGF) [56–58], a neurotrophic factor that promotes the growth, differentiation, and survival of nervous cells, including sensory neurons [59], glial cell line-derived neurotrophic factor (GDNF), which regulates the development and the maintenance of peripheral nerves, neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5), which can support the survival and function of different types of neurons [60], FGF-2, which exerts neuroprotective effects on peripheral nerves and promotes neuron survival during injury [61, 62], and TGFβ, which also regulates neuronal function and plasticity [63]. 6. Interplay with the bacterial flora, also known as microbiota, which contributes to the extracellular microenvironment. Increasing evidence suggests that changes in the healthy microbiota (i.e. microbial dysbiosis), including gut, urinary-tract and prostatic microbes, which are also age-related [64], play a role not only in triggering inflammation, but also in cancer development, progression, and/or treatment outcome. Bacteria produce proteases, including collagenase, elastase, and hyaluronidase, which degrade the ECM [65] and induce inflammation, which sustains ECM remodeling and affects fibroblast functions, as well as the generation of oxygen radicals leading to DNA damage, compensatory epithelial cell proliferation and mutations that drive tumor onset and recurrence [66]. The gut microbiota affects both the stroma and prostatic epithelium through their metabolites [67]. It has been reported that the abundance of short-chain fatty acid (SCFA) producing intestinal bacteria, namely Rikenellaceae, Alistipes, and Lachnospira, is associated with a high-risk of developing PC, and that these bacterial populations are considerably increased in men with high Gleason grade PC [68]. The prostatic microbial ecosystem, which has not been fully explored, also appears to be altered in the PC microenvironment, with reduced overall species diversity in malignant tissue samples compared to benign tissue samples. The Shewanella genera might be associated with malignant transformation, whereas decreased Vibrio parahaemolyticus counts have been associated with the development of treatment resistance, and the Microbacterium sp. appear to be related with advanced stage PC [69]. An increase in Propionibacterium acnes, Herpesviridae and Papillomaviridae families, and Mycoplasma genitalium, has been recently associated with PC development, although the data needs validation in a larger cohort study [70, 71].

Overall, fibroblasts are crucial for maintaining the structural integrity, homeostasis, functions and immune privilege of the prostatic tissue and dysregulation of their function has been implicated in the pathogenesis of prostatic diseases, including benign prostatic hypertrophy (BPH) and PC.

Prostatic stroma in ageing

With advancing age, the prostate undergoes changes, including stromal remodeling, which are implicated in the development of BPH [72] and PC [73]. A key feature of senescence in cells, including stromal fibroblasts, is a widespread change in epigenetic gene expression [74] leading to an increased production and secretion of proinflammatory cytokines, such as GM-CSF, TGFβ, IL-1β, IL-6, IL-8, IL-10, IL-33, and chemokines, such as CXCL12, CXCL1 and CXCL2, and growth factors, such as connective tissue growth factor (CTGF), and angiogenic factors, such as insulin-like growth factor-binding protein 7 (IGFBP7), vascular endothelial growth factor (VEGF), MMPs, plasminogen activator inhibitors (PAIs), tissue-type plasminogen activator (tPA), as well as reactive oxygen species (ROS) [75, 76], and other key signaling proteins that have powerful paracrine effects on both the glandular epithelia [77], with proliferation-stimulating effects, and the surrounding stromal cells leading to fibrosis and chronic inflammation [78].

Proliferation of the prostatic epithelium has been shown to increase up to three times due to paracrine-acting proteins, such as FGF-7, hepatocyte growth factor (HGF), and amphiregulin released by senescent fibroblasts, suggesting that aging-related changes in the prostate microenvironment contribute to the development of PC [79, 80].

Age-associated stromal fibrosis results from the accumulation of extracellular matrix proteins, primarily senescent collagen, endowed with a high content of the glycosaminoglycan hyaluronan (HA), which stimulate epithelial cell proliferation [81], and from the increased fibroblast release of the enzyme lysyl oxidase (Lox), which cross-links collagen fibers promoting collagen maturation, and contributes to extracellular matrix (ECM) remodeling, matrix stiffening and fibrosis [82].

Age-associated chronic inflammation has the hallmarks of immunosuppression and immune evasion and is characterized by MDSCs and Treg cell infiltrates, and by a switch towards M2 and N2, alternatively activated macrophages [83] and neutrophils [84], both endowed with tumor-promoting activity.

As men age and testosterone levels decline, the balance between testosterone and estrogens may shift towards higher estrogen levels, which stimulate the proliferation of prostatic fibroblasts and their production of inflammatory cytokines, resulting in endothelial adhesion molecule expression and immune cell recruitment and activation, which, in turn, impact on endothelial functions [85, 86]. Estrogens also promote prostatic fibroblast production of angiogenic factors, such as FGF-2, EGF, and IGF-1 [87], and collagen, both of which affect endothelial permeability, functions and vascular remodeling [88, 89]. Along with dihydrotestosterone derived from testosterone as a consequence of an age-associated increase in 5-alpha reductase activity [90], estrogens have been implicated in the development of BPH and PC, in which activated and proliferating fibroblasts play a critical role [72, 91, 92].

Androgens can influence the transcriptional programs and inflammatory profile of fibroblasts, leading to an altered inflammatory environment which impacts the functional state of endothelia. Age-associated testosterone deficiency promotes pro-migratory cytokine release by fibroblasts [93] and contributes to chronic inflammation, induces endothelial dysfunction [94, 95], decreases vascularity [96], impairs arterial elasticity and microvascular function [97], and reduces nitric oxide (NO) production [98]. Reduced testosterone levels can contribute to the premature senescence of stromal fibroblasts [99]. Senescent fibroblasts secrete inflammatory and matrix-degrading molecules and are characterized by increased production of reactive oxygen species (ROS) [100]. Following ROS production, the activities of several enzymes of the testosterone biosynthetic pathway are reduced, resulting in further decrease in testosterone synthesis and secretion [101]. Elevated ROS levels can cause oxidative damage to endothelial cells, impairing their function. Endothelial dysfunction [102], defined as a reduced capacity for NO production and decreased NO sensitivity [94] which leads to lower peripheral vasodilation, is a hallmark of vascular ageing [103, 104]. Therefore, inflammation and chronic oxidative stress are associated with vascular ageing [105] and testosterone deficiency [95, 106].

Prostatic stroma in tumor onset and progression

Stromal reactivity in the early stages of prostate carcinogenesis

Alterations of the prostatic stroma, at the cellular and molecular level, are found during prostate carcinogenesis from the early stages. Chronic inflammation [107], hormonal changes [108], high concentrations of ROS [109–111], typically associated with ageing, along with the genetic background [112] promote, in the peripheral zone of the prostatic gland, the development of high-grade prostatic intraepithelial neoplasia (HG-PIN), the first step toward carcinogenesis. This premalignant lesion, consisting of multilayered atypical epithelial cells, endowed with prominent nucleoli, which proliferate within the prostatic duct and acini, is surrounded by a phenotypically and genotypically subverted stroma. Soluble factors, such as serine protease kallikrein-related peptidase 4 (KLK4), which is produced by atypical epithelial cells, promote stromal reactivity [113, 114], by favoring fibroblasts switch to myofibroblasts, which over-express procollagen I and tenascin C [115, 116], that regulate cell adhesion, migration, and signaling, leading to ECM remodeling. KLK4 activates IGF and TGFβ signaling pathways, and protease-activated receptor 1, PAR1, expressed by stromal cells [117], which lead to increased production of pro-tumorigenic and pro-angiogenic factors, such as FGF1 and VEGF [113]. In turn, vimentin+αSMA+myofibroblasts present within the reactive stroma, interact with atypical epithelial cells of the HG-PIN and regulate their behavior, through the release of growth factors and cytokines, such as EGF, VEGF and TGFβ. TGFβ contributes to the establishment of an immunosuppressive microenvironment by promoting Treg cell development and differentiation, through inducing forkhead box p3 (Foxp3) expression [118, 119], and by inhibiting CD8+ T cell activity, thus sustaining immune-escape mechanisms [120].

Phenotypic and genotypic differences between prostatic stroma and prostate cancer stroma

The stroma of PC exhibits cellular and molecular differences compared to normal prostatic stroma, reflecting the altered microenvironment and interactions with cancer cells [92, 121, 122]. Some of the key distinctions are the following.

a. Cellular composition. PC stroma exhibits a loss of well-differentiated smooth muscle cells and increased numbers of mostly activated fibroblasts, namely cancer-associated fibroblasts (CAFs) [123], immune cells, and endothelial cells. Unlike “resting” fibroblasts harboring the normal stroma, CAFs which share co-expression of vimentin and αSMA with MFBs, remain in the “proliferative phase” of the wound healing response by releasing a range of growth factors and cytokines, such as TGFβ, FGFs, HGF, IL-6 [123], which foster tumor growth [124]. Compared to fibroblasts, CAFs overexpress fibroblast activation protein (FAP) (Fig. 1), PDGFRβ, fibroblast specific protein 1 (FSP-1) and αSMA [125] and can be distinguished into functionally distinct subsets of cells with dysregulated expression of genes associated with ECM remodeling, inflammation, angiogenesis, and immune modulation [126, 127]. Epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNA dysregulation, contribute to the reprogramming of stromal cells towards a tumor-promoting and immunosuppressive phenotype. Promoter hypermethylation and silencing of the Ras GTPase-activating protein, RASAL3, which is further promoted by androgen deprivation therapy (ADT), result into Ras signaling activation in CAFs driving macropinocytosis-mediated glutamine synthesis, that provides the PC epithelia with abundant glutamine, which fuels its proliferation and neuroendocrine differentiation [128, 129] The epigenetic silencing of telomerases, due to inhibition of TGFβ signaling via TGFBR2 promoter methylation, leads to the increase in histone methyltransferase, SUV39H1 (which in turn affects histone methylation levels at the telomeric ends), and consequent telomere shortening in stromal CAFs, which is associated with PC progression and mortality [130, 131]. Accumulating evidence shows that noncoding RNAs (ncRNAs) play a critical role in the crosstalk between CAFs and tumor cells. MicroRNAs, which are small, noncoding RNAs, are pivotal regulatory factors for the formation and activation of CAFs and their metabolic reprogramming by tumor cells, whereas exosomal miRNAs, derived from CAFs, affect tumor cell proliferation, metabolism, angiogenesis, metastasis and chemoresistance, ultimately regulating tumor progression [132–134].

Fig. 1 Immunostaining with anti-FAP antibody (#AF3715; R&D Systems, Minneapolis, MN, USA) highlights the absence of CAFs in the stroma of normal prostate tissue (a) and its presence around prostate cancer foci (b). Magnification: X200

Research into the various subtypes of CAFs in PC is still ongoing, but several distinct populations have been identified based on their molecular and functional characteristics. 1. Myofibroblastic CD90highCAFs, characterized by the expression of αSMA, which are involved in ECM remodeling, enhanced matrix stiffness and secretion of growth factors stimulating cancer cell proliferation [135]. 2. Inflammatory CAFs, characterized by the secretion of CCL2, CXCL12, IL-6 and leukocyte inhibiting factor (LIF). They contribute to chronic inflammation within the tumor microenvironment (TME) and facilitate tumor progression by promoting angiogenesis, immune suppression, and epithelial-to-mesenchymal transition (EMT) [135]. 3. Senescent CAFs, which express high levels of αSMA, senescence-associated beta-galactosidase (SA-β-gal) and p16. They undergo cell cycle arrest and reveal a senescence-associated secretory phenotype (SASP), which includes factors that promote tumor cell proliferation, migration, and survival. Senescent CAFs can also induce therapy resistance in PC [136, 137]. 4. Neuroendocrine CD90lowCD105+CAFs, which promote PC progression and are associated with aggressive PC phenotypes, including resistance to ADT and neuroendocrine transdifferentiation [128, 138]. 5. Metabolic CAFs, which undergo metabolic reprogramming to support tumor growth and survival by promoting aerobic glycolysis (the Warburg effect), fatty acid metabolism, and amino acid metabolism. They supply energy substrates (lactate) and biosynthetic precursors to cancer cells, contributing to tumor progression and therapy resistance. The hallmark of this metabolic switch consists in high expression levels of lactic dehydrogenase (LDHA), pyruvate kinase M2 (PKM2) and monocarboxylate transporter 4 (MCT4) [139]. 6. Immunomodulatory CAFs, which inhibit anti-tumor immune responses, promote immune evasion, and contribute to immunotherapy resistance in PC. Immunomodulatory CAFs are represented by CCL2-secreting CAFs, which mainly recruit monocytes/macrophages and Tregs, and inhibit CD8+ T cell effector functions [140–142], and CXCL12-secreting CAFs, which in addition to contributing to tumor cell survival, angiogenesis, desmoplasia and chemoresistance [143], promote the recruitment of MDSCs, M2-phenotype macrophages, and Tregs [144, 145]. These subtypes of CAFs coexist in the PC stroma and exhibit phenotypic plasticity in response to stimuli from the TME [146, 147].

ECM remodeling. During PC development, the ECM undergoes significant changes in composition, organization, and function, which contribute to tumor growth, invasion, metastasis, and therapy resistance.

In the normal prostate tissue, the ECM primarily consists of proteins such as collagen, laminins, fibronectin, and proteoglycans, which provide structural support and regulate cellular functions. In PC, the ECM becomes disorganized and heterogeneous (Fig. 2) and shows an increase in the deposition of collagen, particularly collagen type I, III, IV and V, and of proteoglycans, such as versican, decorin, and perlecan, by CAFs, and alterations in collagen fibers alignment and density, that contribute to stromal stiffness and altered biomechanical properties [148]. Enhanced matrix stiffness promotes M2 phenotype polarization in macrophages, which in turn favor ECM deposition [149]. Higher collagen density has been associated with higher Gleason score suggesting its involvement in PC aggressiveness [115]. Proteomic signature of CAFs versus normal prostate fibroblasts revealed their prominent synthesis of multiple collagens, including the fibrillar types COL1A1/2 and COL5A1; increased activity and/or expression of the receptor tyrosine kinase discoidin domain-containing receptor 2 (DDR2), a receptor for fibrillar collagens; and lysyl oxidase-like 2 (LOXL2), an enzyme that promotes collagen crosslinking [150]. Additionally, there may be aberrant expression of ECM-modifying enzymes, such as MMPs, including upregulation of MMP-2, -7, -9, membrane-type (MT)1-MMP [151]; and downregulation of TIMPs, such as TIMP-1 [152], leading to a substantial ECM remodeling.

Fig. 2 Masson’s trichrome stain (#04-010802; Bio-Optica, Milan, Italy) highlights a regular and well-organized stromal component surrounding the normal prostate glands (a), while the stroma near the neoplastic glands appears more disorganized and dense (b). Magnification: X200

In the normal prostate tissue, the interactions between epithelial cells, stromal cells, and the ECM are tightly regulated and contribute to tissue homeostasis. In PC, neoplastic cells may exhibit enhanced adhesion to specific ECM proteins, allowing them to migrate and invade surrounding tissues. CAFs also subvert androgen biosynthesis in PC cells by secreting glucosamine that specifically upregulate epithelial 3β-Hydroxysteroid dehydrogenase-1 (3βHSD1) expression, and induce androgen synthesis, which leads to androgen receptor activation, development of CRPC and antiandrogen resistance [153]. The type II transmembrane FAP, which is enriched on the surface of CAFs in the PC stroma, has recently proven to be a useful biomarker for diagnosis, through 68Ga-FAP-targeted PET-CT254 imaging [154, 155], and a target for therapy, since FAP-directed ligands carrying therapeutic payloads have shown promising results in cancer patient trials [156, 157]. Increased stromal content of collagen, fibronectin, laminin, abundant expression of secreted protein acidic and rich in cysteine (SPARC/osteonectin) and tenascin C, in association with a downregulation of angiogenesis inhibitors, such as thrombospondin (TSP)-1 and TSP-2 [158–160] are all involved in ECM remodeling, endothelial cell recruitment and angiogenesis [161] and in the development of resistance to therapy [155].

b. Differences between fibrosis and desmoplasia. The term desmoplasia (from the Greek word desmos, to fetter or restrain; and plasis, formation) is used by pathologists to describe the formation of excessive connective tissue around invasive carcinoma [162]. It is characterized by alterations of the tumor stroma that can range from an abundance of cellular elements, such as fibroblasts, vascular cells, and immune cells with little ECM, to the presence of an abundant collagen-rich ECM with a minimum of cells, mainly fibroblasts and myofibroblasts [163]. It is considered as a response to the presence of invasive tumor cells, but the possibility that desmoplasia may precede the presence of malignant cells cannot be ruled out [164]. Fibrosis and desmoplasia are both terms used to describe the abnormal growth of fibrous tissue, however they have distinct characteristics and occur in different contexts. Fibrosis is a pathological process that can occur in response to various insults or injuries, such as inflammation resulting from ageing (IL-8, CXCL5, CXCL1, CXCL6, and CXCL12 secretion by senescent fibroblasts and epithelial cells), infection, or inflammation-associated metabolic diseases (for example, type 2 diabetes mellitus), and is characterized by the excessive accumulation of fibrous connective tissue, primarily collagen, in the stroma. Fibrosis is associated with the loss of normal tissue architecture and can contribute to lower urinary tract dysfunction and BPH [165]. Desmoplasia specifically refers to the growth of dense, fibrous tissue in response to cancer development and involves the deposition of collagen I and fibronectin, and other ECM components, such as proteoglycan syndecan-1, hyaluronic acid and tenascin-C around the tumor. TGFβ signaling from CAFs plays a key role in the structural and mechanical changes that lead to desmoplasia in PC. Desmoplasia and TGFβ induced translocation of SMAD2/3 to the nucleus of PC cells, amplifies their expression of mesenchymal markers, leading to EMT and favoring PC progression [166]. Desmoplasia creates a dense stroma that may help contain the tumor, but that can also create barriers that limit drug delivery and contribute to treatment resistance [167, 168], which ultimately depends on the delicate balance between the different microenvironmental components [169].

c. Immune cell context. In the normal healthy prostate, the immune cell atlas delineates a range of innate and adaptive immune cells, with several CD4+ and CD8+ T cell subsets, including naïve, tissue-resident memory, and regulatory CD4+ T cells, which help maintain immune tolerance and prevent autoimmune reactions, as well as cytotoxic and tissue-resident memory CD8+ T-cell clusters, two subsets of NK cells (CD16+ and CD16−), B cells, mostly mature non-naïve responsible for antibody production, CD1 and CD2 conventional DCs [170], mast cells, which can release histamine and other mediators regulating the local immune environment, monocytes and a prostate-specific metallothionein-expressing macrophage subset (MAC-MT), which regulates prostate zinc and plays homeostatic role that contribute to organ physiology and function [6, 171].

Stromal cells, mostly the CAF subsets, substantially contribute to the immune perturbation that characterize PC development, and exhibit increased expression of genes coding for cytokines, chemokines, and immune cell recruitment factors [172]. Expression of CXCL12 by CAFs, CCL2 by pericytes, along with CCL3,4, and 5 by cancer cells lead to CD16high monocyte and CD14high inflammatory macrophage recruitment [173]. Antigen presenting macrophages with a high “antigen processing and presentation gene signature”, as well as M2-macrophages with a high “M2-gene signature” have been found in the PC stroma and have been shown to suppress the anti-tumor immune response, as observed across a broad range of tumors [173]. High infiltration of M2-macrophages in PC tissue has been linked to tumor recurrence and metastasis [174].

Signals from both the stromal and the epithelial components of PC shape the immunosuppressive TME leading to T cell exhaustion, Treg cell recruitment, accumulation of monocytic (Mo)-MDSCs, endowed with iNOS activity and NO production [175] and granulocytic polymorphonuclear (PMN)-MDSCs that typically produce IL-1β and IL-23, and suppress T cell functions by NADPH-oxidase and ARG1 activities [176]. Expression of programmed death ligand-1/2 PD-L1 and PD-L2, by FAPhigh CAF subset has been recently described, in different tumor types, as well as PD-L1 induction on tumor cells by CXCL5 released by CAFs [177]. Based on its substantial content in CAFs, analogous mechanisms of anti-tumor T cell inhibition may take place in PC and contribute to its immunosuppressive microenvironment [178].

Prognostic value of the prostate cancer stroma

The PC stroma has emerged as a significant factor in predicting disease progression, treatment response, and overall patient outcomes [179]. Stromal cells and ECM components interact closely with cancer cells and influence tumor behavior promoting tumor growth, invasion, and metastasis through various mechanisms, including cytokine signaling, ECM remodeling, and angiogenesis. Deep learning methodologies in combination with mathematical modelling are currently being developed to quantify stromal stains and to allow digital multiplex analyses of cancer stroma components [180]. The key points regarding the prognostic value of the PC stroma are represented by, a. Elevated levels of stromal markers, such as αSMA, fibroblast-specific protein 1 (FSP1), and FAP, which have been associated with aggressive disease, metastasis, and poor prognosis in PC patients [181–183]; b. Increased stromal density, and alterations in stromal morphology and architecture, as assesses by histopathological methods [115], which have been associated with higher Gleason scores, advanced stage disease, and poorer prognosis; c. Copy number alterations and mutations of genes encoding ECM proteins and proteins modulating the ECM structure or function are frequent in cancer [184] and involve the PC stroma with an impact on tumor behavior and clinical outcome. Amplification of COL1A1, COL4A2, and COL6A1 genes and protein overexpression, have been observed in PC and are associated with tumor aggressiveness and metastasis. Aberrant expression of laminins, such as laminin-332, as well as dysregulation of integrins, including αvβ3 and αvβ6, and overexpression of MMPs, particularly MMP-2 and MMP-9, have been implicated in PC progression and metastasis [185]. Overexpression of versican, decorin, and periostin has been reported in PC and is associated with tumor aggressiveness.

Advanced imaging modalities, including magnetic resonance imaging (MRI) and multiparametric MRI (mpMRI), can provide insights into the stromal composition and its spatial distribution within the prostate gland and may complement traditional clinical staging methods. Integrating stromal features into prognostic models and nomograms can improve risk stratification and prediction of disease outcomes in PC patients. Multimodal approaches that incorporate both epithelial and stromal factors may enhance accuracy of prognostic assessments and guide personalized treatment decision-making.

Tumor stroma targeting strategies

As an essential component of the TME, the stroma is highly dynamic, heterogeneous and tumor-type specific. All of its components, which include ECM, CAFs, endothelial cells, pericytes and other mesenchymal cells, interact with each other in a coordinated fashion and collectively promote tumor onset, progression and therapeutic resistance [186, 187]. Clinical trials testing treatments targeting, specifically, the fibroblastic and matrix components of the PC stroma are currently lacking, whilst a study (NCT02452008) testing TGFβ pathway inhibition specifically in mCRPC is ongoing. However, several trials, aimed at subverting the tumor stroma components for anti-cancer purposes, are currently underway [188].

Active trials designed to target CAFs are the following.

•Fibroblast activation protein (FAP) is one of the most studied molecules in trials testing therapies aimed at targeting the tumor stroma, specifically CAFs. The clinical trials NCT05723640, NCT0541082 and NCT05963386 are currently testing the safety and tolerability of two novel FAP-targeted radiopharmaceuticals, 177Lu-LNC1004 and 177Lu-DOTA-EB-FAPI, in various solid tumors, whereas the LuMIERE study (NCT04939610) is evaluating the efficacy of 177Lu-FAP-2286 as a monotherapy in patients with pancreatic ductal adenocarcinoma, non-small cell lung cancer, and breast cancer [189].

•The NCT05626829 study is evaluating the safety and effectiveness of using Tranilast, an anti-allergic drug, as a radiotherapy sensitizer in nasopharyngeal carcinoma, since it was recently discovered, through in vivo and in vitro experiments, that it can inhibit the activity of CAFs and reduce their radiotherapy resistance [190–192].

•Similarly, the NCT06142318 trial is testing the efficacy of Pirfenidone, a drug approved for the treatment of idiopathic pulmonary fibrosis, as a radiosensitizer in head and neck squamous cell carcinoma, since it can enhance the radiosensitivity of CAFs, in vitro and in vivo [193–195].

Active trials designed to target the TGFβ pathway are the following.

•The NCT02452008 study is currently testing the efficacy of Galunisertib (an oral inhibitor of the TGFβ1 type I receptor kinase) in patients with mCRPC. This agent has provided evidence of significant antitumor activity in xenograft models of breast and hepatocellular carcinoma [196–198] and it has been demonstrated to reverse the TGFβ-mediated suppression of NK cell function [199].

•Similarly, the NCT05588648 study, is testing the antitumor activity of Vactosertib (a recently discovered TGFβ1 type I receptor kinase inhibitor) in patients with progressive osteosarcoma. Vactosertib is also being studied in two other trials, NCT05436990 and NCT03143985, which are evaluating its antitumor activity in patients with melanoma or multiple myeloma, respectively.

•Lastly, the NCT05821595 trial is evaluating the efficacy of JYB1907 (a humanized monoclonal antibody directed against the TGFβ activator Glycoprotein A Repetitions Predominant - GARP) in patients with solid tumors. The anti-GARP monoclonal antibody selectively targets and binds to GARP. This specifically blocks the GARP-mediated release of the cytokine TGFβ, thereby reversing the immunosuppressive nature of the tumor microenvironment [200].

A wide range of approaches aimed at targeting the cancer stroma to disrupt its supportive role in tumor growth and metastasis are being studied. Combinations of stroma-targeted therapies with conventional treatments such as chemotherapy, radiation therapy, or immunotherapy can synergistically disrupt stromal support and inhibit tumor progression improving patient outcome.

Acknowledgements

Not applicable.

Author contributions

EDC: Writing – original draft, Writing – review & editing. CS: Data curation, Writing – review & editing. All authors participated in the revision and gave final approval to the manuscript. Both authors reviewed and approved he manuscript.

Funding

The research leading to these results has received funding from: AIRC, under IG 2019 - ID. 23264 project – P.I. Emma Di Carlo; MUR (Ministero dell’Università e della Ricerca) and Programma Operativo Nazionale Ricerca e Innovazione 2014–2020 (PON R&I) to Carlo Sorrentino.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Bray F Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 3 209 49 10.3322/caac.21660 33538338
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. 10.3322/caac.21660.33538338 10.3322/caac.21660
2. Pernar CH Ebot EM Wilson KM Mucci LA The epidemiology of prostate Cancer Cold Spring Harb Perspect Med 2018 8 12 a030361 10.1101/cshperspect.a030361 29311132
Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate Cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. 10.1101/cshperspect.a030361.29311132 10.1101/cshperspect.a030361
3. Desai MM Cacciamani GE Gill K Zhang J Liu L Abreu A Gill IS Trends in incidence of metastatic prostate Cancer in the US JAMA Netw Open 2022 5 3 e222246 10.1001/jamanetworkopen.2022.2246 35285916
Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, Gill IS. Trends in incidence of metastatic prostate Cancer in the US. JAMA Netw Open. 2022;5(3):e222246. 10.1001/jamanetworkopen.2022.2246.35285916 10.1001/jamanetworkopen.2022.2246
4. Hammerstrom AE Cauley DH Atkinson BJ Sharma P Cancer immunotherapy: sipuleucel-T and beyond Pharmacotherapy 2011 31 8 813 28 10.1592/phco.31.8.813 21923608
Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy. 2011;31(8):813–28. 10.1592/phco.31.8.813.21923608 10.1592/phco.31.8.813
5. Sanches BDA Maldarine JS Vilamaior PSL Felisbino SL Carvalho HF Taboga SR Stromal cell interplay in prostate development, physiology, and pathological conditions Prostate 2021 81 13 926 37 10.1002/pros.24196 34254335
Sanches BDA, Maldarine JS, Vilamaior PSL, Felisbino SL, Carvalho HF, Taboga SR. Stromal cell interplay in prostate development, physiology, and pathological conditions. Prostate. 2021;81(13):926–37. 10.1002/pros.24196.34254335 10.1002/pros.24196
6. Tuong ZK Loudon KW Berry B Richoz N Jones J Tan X Nguyen Q George A Hori S Field S Lynch AG Kania K Coupland P Babbage A Grenfell R Barrett T Warren AY Gnanapragasam V Massie C Clatworthy MR Resolving the immune landscape of human prostate at a single-cell level in health and cancer Cell Rep 2021 37 12 110132 10.1016/j.celrep.2021.110132 34936871
Tuong ZK, Loudon KW, Berry B, Richoz N, Jones J, Tan X, Nguyen Q, George A, Hori S, Field S, Lynch AG, Kania K, Coupland P, Babbage A, Grenfell R, Barrett T, Warren AY, Gnanapragasam V, Massie C, Clatworthy MR. Resolving the immune landscape of human prostate at a single-cell level in health and cancer. Cell Rep. 2021;37(12):110132. 10.1016/j.celrep.2021.110132.34936871 10.1016/j.celrep.2021.110132
7. Sutherland SIM Ju X Horvath LG Clark GJ Moving on from Sipuleucel-T: new dendritic cell vaccine strategies for prostate Cancer Front Immunol 2021 12 641307 10.3389/fimmu.2021.641307 33854509
Sutherland SIM, Ju X, Horvath LG, Clark GJ. Moving on from Sipuleucel-T: new dendritic cell vaccine strategies for prostate Cancer. Front Immunol. 2021;12:641307. 10.3389/fimmu.2021.641307.33854509 10.3389/fimmu.2021.641307
8. Cunha GR, Vezina CM, Isaacson D, Ricke WA, Timms BG, Cao M, Franco O, Baskin LS. Development of the human prostate. Differ 2018 Sep-Oct;103:24–45. 10.1016/j.diff.2018.08.005
9. Cunha GR Cao M Derpinghaus A Baskin LS Human urogenital sinus mesenchyme is an inducer of prostatic epithelial development Am J Clin Exp Urol 2021 9 4 329 36 34541031
Cunha GR, Cao M, Derpinghaus A, Baskin LS. Human urogenital sinus mesenchyme is an inducer of prostatic epithelial development. Am J Clin Exp Urol. 2021;9(4):329–36.34541031
10. Timme TL Truong LD Merz VW Krebs T Kadmon D Flanders KC Park SH Thompson TC Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis Endocrinology 1994 134 3 1039 45 10.1210/endo.134.3.8119140 8119140
Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 1994;134(3):1039–45. 10.1210/endo.134.3.8119140.8119140 10.1210/endo.134.3.8119140
11. Fu X Liu G Halim A Ju Y Luo Q Song AG Mesenchymal stem cell Migration and tissue repair Cells 2019 8 8 784 10.3390/cells8080784 31357692
Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell Migration and tissue repair. Cells. 2019;8(8):784. 10.3390/cells8080784.31357692 10.3390/cells8080784
12. Nam D Park A Dubon MJ Yu J Kim W Son Y Park KS Coordinated regulation of Mesenchymal Stem Cell Migration by various chemotactic stimuli Int J Mol Sci 2020 21 22 8561 10.3390/ijms21228561 33202862
Nam D, Park A, Dubon MJ, Yu J, Kim W, Son Y, Park KS. Coordinated regulation of Mesenchymal Stem Cell Migration by various chemotactic stimuli. Int J Mol Sci. 2020;21(22):8561. 10.3390/ijms21228561.33202862 10.3390/ijms21228561
13. Kwon OJ Zhang Y Li Y Wei X Zhang L Chen R Creighton CJ Xin L Functional heterogeneity of mouse prostate stromal cells revealed by single-cell RNA-Seq iScience 2019 13 328 38 10.1016/j.isci.2019.02.032 30878879
Kwon OJ, Zhang Y, Li Y, Wei X, Zhang L, Chen R, Creighton CJ, Xin L. Functional heterogeneity of mouse prostate stromal cells revealed by single-cell RNA-Seq. iScience. 2019;13:328–38. 10.1016/j.isci.2019.02.032.30878879 10.1016/j.isci.2019.02.032
14. Karamanos NK Theocharis AD Piperigkou Z Manou D Passi A Skandalis SS Vynios DH Orian-Rousseau V Ricard-Blum S Schmelzer CEH Duca L Durbeej M Afratis NA Troeberg L Franchi M Masola V Onisto M A guide to the composition and functions of the extracellular matrix FEBS J 2021 288 24 6850 912 10.1111/febs.15776 33605520
Karamanos NK, Theocharis AD, Piperigkou Z, Manou D, Passi A, Skandalis SS, Vynios DH, Orian-Rousseau V, Ricard-Blum S, Schmelzer CEH, Duca L, Durbeej M, Afratis NA, Troeberg L, Franchi M, Masola V, Onisto M. A guide to the composition and functions of the extracellular matrix. FEBS J. 2021;288(24):6850–912. 10.1111/febs.15776.33605520 10.1111/febs.15776
15. Gabbiani G The myofibroblast in wound healing and fibrocontractive diseases J Pathol 2003 200 4 500 3 10.1002/path.1427 12845617
Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200(4):500–3. 10.1002/path.1427.12845617 10.1002/path.1427
16. Brizzi MF Tarone G Defilippi P Extracellular matrix, integrins, and growth factors as tailors of the stem cell niche Curr Opin Cell Biol 2012 24 5 645 51 10.1016/j.ceb.2012.07.001 22898530
Brizzi MF, Tarone G, Defilippi P. Extracellular matrix, integrins, and growth factors as tailors of the stem cell niche. Curr Opin Cell Biol. 2012;24(5):645–51. 10.1016/j.ceb.2012.07.001.22898530 10.1016/j.ceb.2012.07.001
17. Paland N Kamer I Kogan-Sakin I Madar S Goldfinger N Rotter V Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer Mol Cancer Res 2009 7 8 1212 23 10.1158/1541-7786.MCR-09-0073 19671672
Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N, Rotter V. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol Cancer Res. 2009;7(8):1212–23. 10.1158/1541-7786.MCR-09-0073.19671672 10.1158/1541-7786.MCR-09-0073
18. Wen S Chang HC Tian J Shang Z Niu Y Chang C Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer Am J Pathol 2015 185 2 293 301 10.1016/j.ajpath.2014.10.012 25432062
Wen S, Chang HC, Tian J, Shang Z, Niu Y, Chang C. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Am J Pathol. 2015;185(2):293–301. 10.1016/j.ajpath.2014.10.012.25432062 10.1016/j.ajpath.2014.10.012
19. Wei X Zhang L Zhou Z Kwon OJ Zhang Y Nguyen H Dumpit R True L Nelson P Dong B Xue W Birchmeier W Taketo MM Xu F Creighton CJ Ittmann MM Xin L Spatially restricted stromal wnt signaling restrains prostate epithelial progenitor growth through Direct and Indirect mechanisms Cell Stem Cell 2019 24 5 753 e7686 10.1016/j.stem.2019.03.010 30982770
Wei X, Zhang L, Zhou Z, Kwon OJ, Zhang Y, Nguyen H, Dumpit R, True L, Nelson P, Dong B, Xue W, Birchmeier W, Taketo MM, Xu F, Creighton CJ, Ittmann MM, Xin L. Spatially restricted stromal wnt signaling restrains prostate epithelial progenitor growth through Direct and Indirect mechanisms. Cell Stem Cell. 2019;24(5):753–e7686. 10.1016/j.stem.2019.03.010.30982770 10.1016/j.stem.2019.03.010
20. Peng YC Joyner AL Hedgehog signaling in prostate epithelial-mesenchymal growth regulation Dev Biol 2015 400 1 94 104 10.1016/j.ydbio.2015.01.019 25641695
Peng YC, Joyner AL. Hedgehog signaling in prostate epithelial-mesenchymal growth regulation. Dev Biol. 2015;400(1):94–104. 10.1016/j.ydbio.2015.01.019.25641695 10.1016/j.ydbio.2015.01.019
21. Feghali CA Wright TM Cytokines in acute and chronic inflammation Front Biosci 1997 2 d12 26 10.2741/a171 9159205
Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci. 1997;2:d12–26. 10.2741/a171.9159205 10.2741/a171
22. Gharaee-Kermani M McCullumsmith RE Charo IF Kunkel SL Phan SH CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis Cytokine 2003 24 6 266 76 10.1016/j.cyto.2003.08.003 14609568
Gharaee-Kermani M, McCullumsmith RE, Charo IF, Kunkel SL, Phan SH. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine. 2003;24(6):266–76. 10.1016/j.cyto.2003.08.003.14609568 10.1016/j.cyto.2003.08.003
23. Gharaee-Kermani M Kasina S Moore BB Thomas D Mehra R Macoska JA CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis PLoS ONE 2012 7 11 e49278 10.1371/journal.pone.0049278 23173053
Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS ONE. 2012;7(11):e49278. 10.1371/journal.pone.0049278.23173053 10.1371/journal.pone.0049278
24. Scotton CJ Chambers RC Molecular targets in pulmonary fibrosis: the myofibroblast in focus Chest 2007 132 4 1311 21 10.1378/chest.06-2568 17934117
Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132(4):1311–21. 10.1378/chest.06-2568.17934117 10.1378/chest.06-2568
25. Griffith JW Sokol CL Luster AD Chemokines and chemokine receptors: positioning cells for host defense and immunity Annu Rev Immunol 2014 32 659 702 10.1146/annurev-immunol-032713-120145 24655300
Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702. 10.1146/annurev-immunol-032713-120145.24655300 10.1146/annurev-immunol-032713-120145
26. Kitamura H Kamon H Sawa S Park SJ Katunuma N Ishihara K Murakami M Hirano T IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells Immunity 2005 23 5 491 502 10.1016/j.immuni.2005.09.010 16286017
Kitamura H, Kamon H, Sawa S, Park SJ, Katunuma N, Ishihara K, Murakami M, Hirano T. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity. 2005;23(5):491–502. 10.1016/j.immuni.2005.09.010.16286017 10.1016/j.immuni.2005.09.010
27. Tang M Diao J Gu H Khatri I Zhao J Cattral MS Toll-like receptor 2 activation promotes Tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling Cell Rep 2015 13 12 2851 64 10.1016/j.celrep.2015.11.053 26711349
Tang M, Diao J, Gu H, Khatri I, Zhao J, Cattral MS. Toll-like receptor 2 activation promotes Tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep. 2015;13(12):2851–64. 10.1016/j.celrep.2015.11.053.26711349 10.1016/j.celrep.2015.11.053
28. Zhou J Qu Z Sun F Han L Li L Yan S Stabile LP Chen LF Siegfried JM Xiao G Myeloid STAT3 promotes lung tumorigenesis by transforming Tumor Immunosurveillance into Tumor-promoting inflammation Cancer Immunol Res 2017 5 3 257 68 10.1158/2326-6066.CIR-16-0073 28108629
Zhou J, Qu Z, Sun F, Han L, Li L, Yan S, Stabile LP, Chen LF, Siegfried JM, Xiao G. Myeloid STAT3 promotes lung tumorigenesis by transforming Tumor Immunosurveillance into Tumor-promoting inflammation. Cancer Immunol Res. 2017;5(3):257–68. 10.1158/2326-6066.CIR-16-0073.28108629 10.1158/2326-6066.CIR-16-0073
29. Tsukamoto H Fujieda K Senju S Ikeda T Oshiumi H Nishimura Y Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity Cancer Sci 2018 109 3 523 30 10.1111/cas.13433 29090850
Tsukamoto H, Fujieda K, Senju S, Ikeda T, Oshiumi H, Nishimura Y. Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity. Cancer Sci. 2018;109(3):523–30. 10.1111/cas.13433.29090850 10.1111/cas.13433
30. Bazzaz JT Amoli MM Taheri Z Larijani B Pravica V Hutchinson IV TNF-α and IFN-γ gene variation and genetic susceptibility to type 1 diabetes and its microangiopathic complications J Diabetes Metab Disord 2014 13 46 10.1186/2251-6581-13-46 24693923
Bazzaz JT, Amoli MM, Taheri Z, Larijani B, Pravica V, Hutchinson IV. TNF-α and IFN-γ gene variation and genetic susceptibility to type 1 diabetes and its microangiopathic complications. J Diabetes Metab Disord. 2014;13:46. 10.1186/2251-6581-13-46.24693923 10.1186/2251-6581-13-46
31. Beyer M Abdullah Z Chemnitz JM Maisel D Sander J Lehmann C Thabet Y Shinde PV Schmidleithner L Köhne M Trebicka J Schierwagen R Hofmann A Popov A Lang KS Oxenius A Buch T Kurts C Heikenwalder M Fätkenheuer G Lang PA Hartmann P Knolle PA Schultze JL Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection Nat Immunol 2016 17 5 593 603 10.1038/ni.3399 26950238
Beyer M, Abdullah Z, Chemnitz JM, Maisel D, Sander J, Lehmann C, Thabet Y, Shinde PV, Schmidleithner L, Köhne M, Trebicka J, Schierwagen R, Hofmann A, Popov A, Lang KS, Oxenius A, Buch T, Kurts C, Heikenwalder M, Fätkenheuer G, Lang PA, Hartmann P, Knolle PA, Schultze JL. Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. Nat Immunol. 2016;17(5):593–603. 10.1038/ni.3399.26950238 10.1038/ni.3399
32. Ban L Zhang J Wang L Kuhtreiber W Burger D Faustman DL Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism Proc Natl Acad Sci U S A 2008 105 36 13644 9 10.1073/pnas.0803429105 18755894
Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci U S A. 2008;105(36):13644–9. 10.1073/pnas.0803429105.18755894 10.1073/pnas.0803429105
33. Hu X Li B Li X Zhao X Wan L Lin G Yu M Wang J Jiang X Feng W Qin Z Yin B Li Z Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2 J Immunol 2014 192 3 1320 31 10.4049/jimmunol.1203195 24379122
Hu X, Li B, Li X, Zhao X, Wan L, Lin G, Yu M, Wang J, Jiang X, Feng W, Qin Z, Yin B, Li Z. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J Immunol. 2014;192(3):1320–31. 10.4049/jimmunol.1203195.24379122 10.4049/jimmunol.1203195
34. Zhao X Rong L Zhao X Li X Liu X Deng J Wu H Xu X Erben U Wu P Syrbe U Sieper J Qin Z TNF signaling drives myeloid-derived suppressor cell accumulation J Clin Invest 2012 122 11 4094 104 10.1172/JCI64115 23064360
Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J, Wu H, Xu X, Erben U, Wu P, Syrbe U, Sieper J, Qin Z. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122(11):4094–104. 10.1172/JCI64115.23064360 10.1172/JCI64115
35. Chen X Bäumel M Männel DN Howard OM Oppenheim JJ Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4 + CD25 + T regulatory cells J Immunol 2007 179 1 154 61 10.4049/jimmunol.179.1.154 17579033
Chen X, Bäumel M, Männel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4 + CD25 + T regulatory cells. J Immunol. 2007;179(1):154–61. 10.4049/jimmunol.179.1.154.17579033 10.4049/jimmunol.179.1.154
36. Chen X Subleski JJ Kopf H Howard OM Männel DN Oppenheim JJ Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4 + CD25 + FoxP3 + T regulatory cells: applicability to tumor-infiltrating T regulatory cells J Immunol 2008 180 10 6467 71 10.4049/jimmunol.180.10.6467 18453563
Chen X, Subleski JJ, Kopf H, Howard OM, Männel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4 + CD25 + FoxP3 + T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol. 2008;180(10):6467–71. 10.4049/jimmunol.180.10.6467.18453563 10.4049/jimmunol.180.10.6467
37. Kiss M Vande Walle L Saavedra PHV Lebegge E Van Damme H Murgaski A Qian J Ehling M Pretto S Bolli E Keirsse J Bardet PMR Arnouk SM Elkrim Y Schmoetten M Brughmans J Debraekeleer A Fossoul A Boon L Raes G van Loo G Lambrechts D Mazzone M Beschin A Wullaert A Lamkanfi M Van Ginderachter JA Laoui D IL1β promotes Immune suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D Cancer Immunol Res 2021 9 3 309 23 10.1158/2326-6066.CIR-20-0431 33361087
Kiss M, Vande Walle L, Saavedra PHV, Lebegge E, Van Damme H, Murgaski A, Qian J, Ehling M, Pretto S, Bolli E, Keirsse J, Bardet PMR, Arnouk SM, Elkrim Y, Schmoetten M, Brughmans J, Debraekeleer A, Fossoul A, Boon L, Raes G, van Loo G, Lambrechts D, Mazzone M, Beschin A, Wullaert A, Lamkanfi M, Van Ginderachter JA, Laoui D. IL1β promotes Immune suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D. Cancer Immunol Res. 2021;9(3):309–23. 10.1158/2326-6066.CIR-20-0431.33361087 10.1158/2326-6066.CIR-20-0431
38. Wu J Chen Z Wickström SL Gao J He X Jing X Wu J Du Q Yang M Chen Y Zhang D Yin X Guo Z Jensen L Yang Y Tao W Lundqvist A Kiessling R Cao Y Interleukin-33 is a Novel Immunosuppressor that protects Cancer cells from TIL killing by a macrophage-mediated shedding mechanism Adv Sci (Weinh) 2021 8 21 e2101029 10.1002/advs.202101029 34486239
Wu J, Chen Z, Wickström SL, Gao J, He X, Jing X, Wu J, Du Q, Yang M, Chen Y, Zhang D, Yin X, Guo Z, Jensen L, Yang Y, Tao W, Lundqvist A, Kiessling R, Cao Y. Interleukin-33 is a Novel Immunosuppressor that protects Cancer cells from TIL killing by a macrophage-mediated shedding mechanism. Adv Sci (Weinh). 2021;8(21):e2101029. 10.1002/advs.202101029.34486239 10.1002/advs.202101029
39. Siede J Fröhlich A Datsi A Hegazy AN Varga DV Holecska V Saito H Nakae S Löhning M IL-33 receptor-expressing Regulatory T cells are highly activated, Th2 biased and suppress CD4 T cell proliferation through IL-10 and TGFβ release PLoS ONE 2016 11 8 e0161507 10.1371/journal.pone.0161507 27548066
Siede J, Fröhlich A, Datsi A, Hegazy AN, Varga DV, Holecska V, Saito H, Nakae S, Löhning M. IL-33 receptor-expressing Regulatory T cells are highly activated, Th2 biased and suppress CD4 T cell proliferation through IL-10 and TGFβ release. PLoS ONE. 2016;11(8):e0161507. 10.1371/journal.pone.0161507.27548066 10.1371/journal.pone.0161507
40. David CJ Massagué J Contextual determinants of TGFβ action in development, immunity and cancer Nat Rev Mol Cell Biol 2018 19 7 419 35 10.1038/s41580-018-0007-0 29643418
David CJ, Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):419–35. 10.1038/s41580-018-0007-0.29643418 10.1038/s41580-018-0007-0
41. D’Orazio TJ Niederkorn JY A novel role for TGF-beta and IL-10 in the induction of immune privilege J Immunol 1998 160 5 2089 98 10.4049/jimmunol.160.5.2089 9498745
D’Orazio TJ, Niederkorn JY. A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol. 1998;160(5):2089–98.9498745 10.4049/jimmunol.160.5.2089
42. Vaux DL Immunology. Ways around rejection Nature 1995 377 6550 576 7 10.1038/377576a0 7566165
Vaux DL. Immunology. Ways around rejection. Nature. 1995;377(6550):576–7. 10.1038/377576a0.7566165 10.1038/377576a0
43. Green DR Ferguson TA The role of Fas ligand in immune privilege Nat Rev Mol Cell Biol 2001 2 12 917 24 10.1038/35103104 11733771
Green DR, Ferguson TA. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol. 2001;2(12):917–24. 10.1038/35103104.11733771 10.1038/35103104
44. Mellor AL Munn DH Creating immune privilege: active local suppression that benefits friends, but protects foes Nat Rev Immunol 2008 8 1 74 80 10.1038/nri2233 18064049
Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8(1):74–80. 10.1038/nri2233.18064049 10.1038/nri2233
45. Lizée G Radvanyi LG Overwijk WW Hwu P Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms Clin Cancer Res 2006 12 16 4794 803 10.1158/1078-0432.CCR-06-0944 16914564
Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 2006;12(16):4794–803. 10.1158/1078-0432.CCR-06-0944.16914564 10.1158/1078-0432.CCR-06-0944
46. Khalili JS Liu S Rodríguez-Cruz TG Whittington M Wardell S Liu C Zhang M Cooper ZA Frederick DT Li Y Zhang M Joseph RW Bernatchez C Ekmekcioglu S Grimm E Radvanyi LG Davis RE Davies MA Wargo JA Hwu P Lizée G Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma Clin Cancer Res 2012 18 19 5329 40 10.1158/1078-0432.CCR-12-1632 22850568
Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012;18(19):5329–40. 10.1158/1078-0432.CCR-12-1632.22850568 10.1158/1078-0432.CCR-12-1632
47. Kawasaki K Noma K Kato T Ohara T Tanabe S Takeda Y Matsumoto H Nishimura S Kunitomo T Akai M Kobayashi T Nishiwaki N Kashima H Maeda N Kikuchi S Tazawa H Shirakawa Y Fujiwara T PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer Cancer Immunol Immunother 2023 72 11 3787 802 10.1007/s00262-023-03531-2 37668710
Kawasaki K, Noma K, Kato T, Ohara T, Tanabe S, Takeda Y, Matsumoto H, Nishimura S, Kunitomo T, Akai M, Kobayashi T, Nishiwaki N, Kashima H, Maeda N, Kikuchi S, Tazawa H, Shirakawa Y, Fujiwara T. PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer. Cancer Immunol Immunother. 2023;72(11):3787–802. 10.1007/s00262-023-03531-2.37668710 10.1007/s00262-023-03531-2
48. Kraman M Bambrough PJ Arnold JN Roberts EW Magiera L Jones JO Gopinathan A Tuveson DA Fearon DT Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha Science 2010 330 6005 827 30 10.1126/science.1195300 21051638
Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330(6005):827–30. 10.1126/science.1195300.21051638 10.1126/science.1195300
49. Sarkhosh K Tredget EE Karami A Uludag H Iwashina T Kilani RT Ghahary A Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG) J Cell Biochem 2003 90 1 206 17 10.1002/jcb.10593 12938169
Sarkhosh K, Tredget EE, Karami A, Uludag H, Iwashina T, Kilani RT, Ghahary A. Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG). J Cell Biochem. 2003;90(1):206–17. 10.1002/jcb.10593.12938169 10.1002/jcb.10593
50. Curran TA Jalili RB Farrokhi A Ghahary A IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells Immunobiology 2014 219 1 17 24 10.1016/j.imbio.2013.06.008 23891282
Curran TA, Jalili RB, Farrokhi A, Ghahary A. IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells. Immunobiology. 2014;219(1):17–24. 10.1016/j.imbio.2013.06.008.23891282 10.1016/j.imbio.2013.06.008
51. Li A Dubey S Varney ML Dave BJ Singh RK IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis J Immunol 2003 170 6 3369 76 10.4049/jimmunol.170.6.3369 12626597
Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170(6):3369–76. 10.4049/jimmunol.170.6.3369.12626597 10.4049/jimmunol.170.6.3369
52. Salcedo R Oppenheim JJ Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses Microcirculation 2003 10 3–4 359 70 10.1038/sj.mn.7800200 12851652
Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation. 2003;10(3–4):359–70. 10.1038/sj.mn.7800200.12851652 10.1038/sj.mn.7800200
53. Begley LA Kasina S MacDonald J Macoska JA The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy Cytokine 2008 43 2 194 9 10.1016/j.cyto.2008.05.012 18572414
Begley LA, Kasina S, MacDonald J, Macoska JA. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43(2):194–9. 10.1016/j.cyto.2008.05.012.18572414 10.1016/j.cyto.2008.05.012
54. Sorrentino C D’Antonio L Ciummo SL Fieni C Landuzzi L Ruzzi F Vespa S Lanuti P Lotti LV Lollini PL Di Carlo E CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality J Hematol Oncol 2022 15 1 145 10.1186/s13045-022-01357-6 36224639
Sorrentino C, D’Antonio L, Ciummo SL, Fieni C, Landuzzi L, Ruzzi F, Vespa S, Lanuti P, Lotti LV, Lollini PL, Di Carlo E. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality. J Hematol Oncol. 2022;15(1):145. 10.1186/s13045-022-01357-6.36224639 10.1186/s13045-022-01357-6
55. Cambier S Gouwy M Proost P The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention Cell Mol Immunol 2023 20 3 217 51 10.1038/s41423-023-00974-6 36725964
Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023;20(3):217–51. 10.1038/s41423-023-00974-6.36725964 10.1038/s41423-023-00974-6
56. Olgart C Frossard N Human lung fibroblasts secrete nerve growth factor: effect of inflammatory cytokines and glucocorticoids Eur Respir J 2001 18 1 115 21 10.1183/09031936.01.00069901 11510781
Olgart C, Frossard N. Human lung fibroblasts secrete nerve growth factor: effect of inflammatory cytokines and glucocorticoids. Eur Respir J. 2001;18(1):115–21. 10.1183/09031936.01.00069901.11510781 10.1183/09031936.01.00069901
57. Chmilewsky F Ayaz W Appiah J About I Chung SH Nerve growth factor secretion from pulp fibroblasts is modulated by complement C5a receptor and implied in Neurite Outgrowth Sci Rep 2016 6 31799 10.1038/srep31799 27539194
Chmilewsky F, Ayaz W, Appiah J, About I, Chung SH. Nerve growth factor secretion from pulp fibroblasts is modulated by complement C5a receptor and implied in Neurite Outgrowth. Sci Rep. 2016;6:31799. 10.1038/srep31799.27539194 10.1038/srep31799
58. Manni L, Lundeberg T, Fiorito S, Bonini S, Vigneti E, Aloe L. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheumatol. 2003 Sep-Oct;21(5):617–24.
59. Rocco ML Soligo M Manni L Aloe L Nerve growth factor: early studies and recent clinical trials Curr Neuropharmacol 2018 16 10 1455 65 10.2174/1570159X16666180412092859 29651949
Rocco ML, Soligo M, Manni L, Aloe L. Nerve growth factor: early studies and recent clinical trials. Curr Neuropharmacol. 2018;16(10):1455–65. 10.2174/1570159X16666180412092859.29651949 10.2174/1570159X16666180412092859
60. Huang EJ Reichardt LF Neurotrophins: roles in neuronal development and function Annu Rev Neurosci 2001 24 677 736 10.1146/annurev.neuro.24.1.677 11520916
Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736. 10.1146/annurev.neuro.24.1.677.11520916 10.1146/annurev.neuro.24.1.677
61. Kasai M Jikoh T Fukumitsu H Furukawa S FGF-2-responsive and spinal cord-resident cells improve locomotor function after spinal cord injury J Neurotrauma 2014 31 18 1584 98 10.1089/neu.2009.1108 20199141
Kasai M, Jikoh T, Fukumitsu H, Furukawa S. FGF-2-responsive and spinal cord-resident cells improve locomotor function after spinal cord injury. J Neurotrauma. 2014;31(18):1584–98. 10.1089/neu.2009.1108.20199141 10.1089/neu.2009.1108
62. Kang CE Baumann MD Tator CH Shoichet MS Localized and sustained delivery of fibroblast growth factor-2 from a nanoparticle-hydrogel composite for treatment of spinal cord injury Cells Tissues Organs 2013 197 1 55 63 10.1159/000339589 22796886
Kang CE, Baumann MD, Tator CH, Shoichet MS. Localized and sustained delivery of fibroblast growth factor-2 from a nanoparticle-hydrogel composite for treatment of spinal cord injury. Cells Tissues Organs. 2013;197(1):55–63. 10.1159/000339589.22796886 10.1159/000339589
63. Meyers EA Kessler JA TGF-β Family Signaling in neural and neuronal differentiation, Development, and function Cold Spring Harb Perspect Biol 2017 9 8 a022244 10.1101/cshperspect.a022244 28130363
Meyers EA, Kessler JA. TGF-β Family Signaling in neural and neuronal differentiation, Development, and function. Cold Spring Harb Perspect Biol. 2017;9(8):a022244. 10.1101/cshperspect.a022244.28130363 10.1101/cshperspect.a022244
64. Lewis DA Brown R Williams J White P Jacobson SK Marchesi JR Drake MJ The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults Front Cell Infect Microbiol 2013 3 41 10.3389/fcimb.2013.00041 23967406
Lewis DA, Brown R, Williams J, White P, Jacobson SK, Marchesi JR, Drake MJ. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. Front Cell Infect Microbiol. 2013;3:41. 10.3389/fcimb.2013.00041.23967406 10.3389/fcimb.2013.00041
65. Lyczak JB Cannon CL Pier GB Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist Microbes Infect 2000 2 9 1051 60 10.1016/s1286-4579(00)01259-4 10967285
Lyczak JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2000;2(9):1051–60. 10.1016/s1286-4579(00)01259-4.10967285 10.1016/s1286-4579(00)01259-4
66. Kiraly O Gong G Olipitz W Muthupalani S Engelward BP Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo PLoS Genet 2015 11 2 e1004901 10.1371/journal.pgen.1004901 25647331
Kiraly O, Gong G, Olipitz W, Muthupalani S, Engelward BP. Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo. PLoS Genet. 2015;11(2):e1004901. 10.1371/journal.pgen.1004901.25647331 10.1371/journal.pgen.1004901
67. Fujita K Matsushita M Banno E De Velasco MA Hatano K Nonomura N Uemura H Gut microbiome and prostate cancer Int J Urol 2022 29 8 793 8 10.1111/iju.14894 35388531
Fujita K, Matsushita M, Banno E, De Velasco MA, Hatano K, Nonomura N, Uemura H. Gut microbiome and prostate cancer. Int J Urol. 2022;29(8):793–8. 10.1111/iju.14894.35388531 10.1111/iju.14894
68. Matsushita M Fujita K Motooka D Hatano K Fukae S Kawamura N Tomiyama E Hayashi Y Banno E Takao T Takada S Yachida S Uemura H Nakamura S Nonomura N The gut microbiota associated with high-gleason prostate cancer Cancer Sci 2021 112 8 3125 35 10.1111/cas.14998 34051009
Matsushita M, Fujita K, Motooka D, Hatano K, Fukae S, Kawamura N, Tomiyama E, Hayashi Y, Banno E, Takao T, Takada S, Yachida S, Uemura H, Nakamura S, Nonomura N. The gut microbiota associated with high-gleason prostate cancer. Cancer Sci. 2021;112(8):3125–35. 10.1111/cas.14998.34051009 10.1111/cas.14998
69. Salachan PV Rasmussen M Fredsøe J Ulhøi B Borre M Sørensen KD Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling Genome Med 2022 14 1 9 10.1186/s13073-022-01011-3 35078527
Salachan PV, Rasmussen M, Fredsøe J, Ulhøi B, Borre M, Sørensen KD. Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling. Genome Med. 2022;14(1):9. 10.1186/s13073-022-01011-3.35078527 10.1186/s13073-022-01011-3
70. Ward Grados DF Ergun O Miller CD Gaburak P Frimpong NA Shittu O Warlick CA Prostate tissue microbiome in patients with prostate Cancer: a systematic review Cancers (Basel) 2024 16 8 1549 10.3390/cancers16081549 38672631
Ward Grados DF, Ergun O, Miller CD, Gaburak P, Frimpong NA, Shittu O, Warlick CA. Prostate tissue microbiome in patients with prostate Cancer: a systematic review. Cancers (Basel). 2024;16(8):1549. 10.3390/cancers16081549.38672631 10.3390/cancers16081549
71. Sarkar P Malik S Banerjee A Datta C Pal DK Ghosh A Saha A Differential Microbial signature Associated with Benign Prostatic Hyperplasia and prostate Cancer Front Cell Infect Microbiol 2022 12 894777 10.3389/fcimb.2022.894777 35865814
Sarkar P, Malik S, Banerjee A, Datta C, Pal DK, Ghosh A, Saha A. Differential Microbial signature Associated with Benign Prostatic Hyperplasia and prostate Cancer. Front Cell Infect Microbiol. 2022;12:894777. 10.3389/fcimb.2022.894777.35865814 10.3389/fcimb.2022.894777
72. Pollack AS Kunder CA Brazer N Shen Z Varma S West RB Cunha GR Baskin LS Brooks JD Pollack JR Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia JCI Insight 2024 9 2 e176479 10.1172/jci.insight.176479 37971878
Pollack AS, Kunder CA, Brazer N, Shen Z, Varma S, West RB, Cunha GR, Baskin LS, Brooks JD, Pollack JR. Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia. JCI Insight. 2024;9(2):e176479. 10.1172/jci.insight.176479.37971878 10.1172/jci.insight.176479
73. Pederzoli F Raffo M Pakula H Ravera F Nuzzo PV Loda M Stromal cells in prostate cancer pathobiology: friends or foes? Br J Cancer 2023 128 6 930 9 10.1038/s41416-022-02085-x 36482187
Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PV, Loda M. Stromal cells in prostate cancer pathobiology: friends or foes? Br J Cancer. 2023;128(6):930–9. 10.1038/s41416-022-02085-x.36482187 10.1038/s41416-022-02085-x
74. Dean JP Nelson PS Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis Br J Cancer 2008 98 2 245 9 10.1038/sj.bjc.6604087 18182995
Dean JP, Nelson PS. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer. 2008;98(2):245–9. 10.1038/sj.bjc.6604087. Epub 2008 Jan 8. PMID: 18182995; PMCID: PMC2361445.18182995 10.1038/sj.bjc.6604087
75. Amara U Flierl MA Rittirsch D Klos A Chen H Acker B Brückner UB Nilsson B Gebhard F Lambris JD Huber-Lang M Molecular intercommunication between the complement and coagulation systems J Immunol 2010 185 9 5628 36 10.4049/jimmunol.0903678 20870944
Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185(9):5628–36. 10.4049/jimmunol.0903678.20870944 10.4049/jimmunol.0903678
76. Bondi CD Manickam N Lee DY Block K Gorin Y Abboud HE Barnes JL NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts J Am Soc Nephrol 2010 21 1 93 102 10.1681/ASN.2009020146 19926889
Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, Barnes JL. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol. 2010;21(1):93–102. 10.1681/ASN.2009020146.19926889 10.1681/ASN.2009020146
77. Dean JP Nelson PS Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis Br J Cancer 2008 98 2 245 9 10.1038/sj.bjc.6604087 18182995
Dean JP, Nelson PS. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer. 2008;98(2):245–9. 10.1038/sj.bjc.6604087.18182995 10.1038/sj.bjc.6604087
78. Fane M Weeraratna AT How the ageing microenvironment influences tumour progression Nat Rev Cancer 2020 20 2 89 106 10.1038/s41568-019-0222-9 31836838
Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89–106. 10.1038/s41568-019-0222-9.31836838 10.1038/s41568-019-0222-9
79. Bavik C Coleman I Dean JP Knudsen B Plymate S Nelson PS The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms Cancer Res 2006 66 2 794 802 10.1158/0008-5472.CAN-05-1716 16424011
Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006;66(2):794–802. 10.1158/0008-5472.CAN-05-1716.16424011 10.1158/0008-5472.CAN-05-1716
80. Berben L Floris G Wildiers H Hatse S Cancer and Aging: two tightly interconnected biological processes Cancers (Basel) 2021 13 6 1400 10.3390/cancers13061400 33808654
Berben L, Floris G, Wildiers H, Hatse S. Cancer and Aging: two tightly interconnected biological processes. Cancers (Basel). 2021;13(6):1400. 10.3390/cancers13061400.33808654 10.3390/cancers13061400
81. Damodarasamy M Vernon RB Chan CK Plymate SR Wight TN Reed MJ Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation Vitro Cell Dev Biol Anim 2015 51 1 50 8 10.1007/s11626-014-9800-z
Damodarasamy M, Vernon RB, Chan CK, Plymate SR, Wight TN, Reed MJ. Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation. Vitro Cell Dev Biol Anim. 2015;51(1):50–8. 10.1007/s11626-014-9800-z.10.1007/s11626-014-9800-z
82. Kendall RT Feghali-Bostwick CA Fibroblasts in fibrosis: novel roles and mediators Front Pharmacol 2014 5 123 10.3389/fphar.2014.00123 24904424
Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:123. 10.3389/fphar.2014.00123.24904424 10.3389/fphar.2014.00123
83. Liu J Geng X Hou J Wu G New insights into M1/M2 macrophages: key modulators in cancer progression Cancer Cell Int 2021 21 1 389 10.1186/s12935-021-02089-2 34289846
Liu J, Geng X, Hou J, Wu G. New insights into M1/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21(1):389. 10.1186/s12935-021-02089-2.34289846 10.1186/s12935-021-02089-2
84. Wang X Qiu L Li Z Wang XY Yi H Understanding the multifaceted role of neutrophils in Cancer and Autoimmune diseases Front Immunol 2018 9 2456 10.3389/fimmu.2018.02456 30473691
Wang X, Qiu L, Li Z, Wang XY, Yi H. Understanding the multifaceted role of neutrophils in Cancer and Autoimmune diseases. Front Immunol. 2018;9:2456. 10.3389/fimmu.2018.02456. PMID: 30473691; PMCID: PMC6237929.30473691 10.3389/fimmu.2018.02456
85. Mantovani A Bussolino F Dejana E Cytokine regulation of endothelial cell function FASEB J 1992 6 8 2591 9 10.1096/fasebj.6.8.1592209 1592209
Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 1992;6(8):2591–9. 10.1096/fasebj.6.8.1592209.1592209 10.1096/fasebj.6.8.1592209
86. Zhang C The role of inflammatory cytokines in endothelial dysfunction Basic Res Cardiol 2008 103 5 398 406 10.1007/s00395-008-0733-0 18600364
Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008;103(5):398–406. 10.1007/s00395-008-0733-0.18600364 10.1007/s00395-008-0733-0
87. Hervé MA Meduri G Petit FG Domet TS Lazennec G Mourah S Perrot-Applanat M Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus J Endocrinol 2006 188 1 91 9 10.1677/joe.1.06184 16394178
Hervé MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S, Perrot-Applanat M. Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. J Endocrinol. 2006;188(1):91–9.16394178 10.1677/joe.1.06184
88. Theofilis P Sagris M Oikonomou E Antonopoulos AS Siasos G Tsioufis C Tousoulis D Inflammatory mechanisms contributing to endothelial dysfunction Biomedicines 2021 9 7 781 10.3390/biomedicines9070781 34356845
Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis C, Tousoulis D. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines. 2021;9(7):781.34356845 10.3390/biomedicines9070781
89. Lau KM To KF Importance of Estrogenic Signaling and its mediated receptors in prostate Cancer Int J Mol Sci 2016 17 9 1434 10.3390/ijms17091434 27589731
Lau KM, To KF. Importance of Estrogenic Signaling and its mediated receptors in prostate Cancer. Int J Mol Sci. 2016;17(9):1434. 10.3390/ijms17091434.27589731 10.3390/ijms17091434
90. Welén K Damber JE Androgens, aging, and prostate health Rev Endocr Metab Disord 2022 23 6 1221 31 10.1007/s11154-022-09730-z 35748976
Welén K, Damber JE. Androgens, aging, and prostate health. Rev Endocr Metab Disord. 2022;23(6):1221–31. 10.1007/s11154-022-09730-z.35748976 10.1007/s11154-022-09730-z
91. Madersbacher S Sampson N Culig Z Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: a Mini-review Gerontology 2019 65 5 458 64 10.1159/000496289 30943489
Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: a Mini-review. Gerontology. 2019;65(5):458–64. 10.1159/000496289.30943489 10.1159/000496289
92. Bonollo F Thalmann GN Kruithof-de Julio M Karkampouna S The role of Cancer-Associated fibroblasts in prostate Cancer tumorigenesis Cancers (Basel) 2020 12 7 1887 10.3390/cancers12071887 32668821
Bonollo F, Thalmann GN, Kruithof-de Julio M, Karkampouna S. The role of Cancer-Associated fibroblasts in prostate Cancer tumorigenesis. Cancers (Basel). 2020;12(7):1887. 10.3390/cancers12071887.32668821 10.3390/cancers12071887
93. Cioni B Nevedomskaya E Melis MHM van Burgsteden J Stelloo S Hodel E Spinozzi D de Jong J van der Poel H de Boer JP Wessels LFA Zwart W Bergman AM Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration Mol Oncol 2018 12 8 1308 23 10.1002/1878-0261.12327 29808619
Cioni B, Nevedomskaya E, Melis MHM, van Burgsteden J, Stelloo S, Hodel E, Spinozzi D, de Jong J, van der Poel H, de Boer JP, Wessels LFA, Zwart W, Bergman AM. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration. Mol Oncol. 2018;12(8):1308–23. 10.1002/1878-0261.12327.29808619 10.1002/1878-0261.12327
94. Hotta Y Kataoka T Kimura K Testosterone Deficiency and endothelial dysfunction: nitric oxide, asymmetric dimethylarginine, and endothelial progenitor cells Sex Med Rev 2019 7 4 661 8 10.1016/j.sxmr.2019.02.005 30987932
Hotta Y, Kataoka T, Kimura K. Testosterone Deficiency and endothelial dysfunction: nitric oxide, asymmetric dimethylarginine, and endothelial progenitor cells. Sex Med Rev. 2019;7(4):661–8. 10.1016/j.sxmr.2019.02.005.30987932 10.1016/j.sxmr.2019.02.005
95. Babcock MC DuBose LE Witten TL Stauffer BL Hildreth KL Schwartz RS Kohrt WM Moreau KL Oxidative stress and inflammation are Associated with Age-related endothelial dysfunction in men with low testosterone J Clin Endocrinol Metab 2022 107 2 e500 14 10.1210/clinem/dgab715 34597384
Babcock MC, DuBose LE, Witten TL, Stauffer BL, Hildreth KL, Schwartz RS, Kohrt WM, Moreau KL. Oxidative stress and inflammation are Associated with Age-related endothelial dysfunction in men with low testosterone. J Clin Endocrinol Metab. 2022;107(2):e500–14. 10.1210/clinem/dgab715.34597384 10.1210/clinem/dgab715
96. Hofer MD Kapur P Cordon BH Hamoun F Russell D Scott JM Roehrborn CG Morey AF Low testosterone levels result in decreased Periurethral Vascularity via an androgen receptor-mediated process: pilot study in Urethral stricture tissue Urology 2017 105 175 80 10.1016/j.urology.2017.02.037 28263822
Hofer MD, Kapur P, Cordon BH, Hamoun F, Russell D, Scott JM, Roehrborn CG, Morey AF. Low testosterone levels result in decreased Periurethral Vascularity via an androgen receptor-mediated process: pilot study in Urethral stricture tissue. Urology. 2017;105:175–80. 10.1016/j.urology.2017.02.037.28263822 10.1016/j.urology.2017.02.037
97. Corrigan FE 3rd Al Mheid I Eapen DJ Hayek SS Sher S Martin GS Quyyumi AA Low testosterone in men predicts impaired arterial elasticity and microvascular function Int J Cardiol 2015 194 94 9 10.1016/j.ijcard.2015.05.065 26022684
Corrigan FE 3rd, Al Mheid I, Eapen DJ, Hayek SS, Sher S, Martin GS, Quyyumi AA. Low testosterone in men predicts impaired arterial elasticity and microvascular function. Int J Cardiol. 2015;194:94–9. 10.1016/j.ijcard.2015.05.065.26022684 10.1016/j.ijcard.2015.05.065
98. Vargas F Moreno JM Wangensteen R Rodríguez-Gómez I García-Estañ J The endocrine system in chronic nitric oxide deficiency Eur J Endocrinol 2007 156 1 1 12 10.1530/eje.1.02314 17218720
Vargas F, Moreno JM, Wangensteen R, Rodríguez-Gómez I, García-Estañ J. The endocrine system in chronic nitric oxide deficiency. Eur J Endocrinol. 2007;156(1):1–12. 10.1530/eje.1.02314.17218720 10.1530/eje.1.02314
99. Mori JO Elhussin I Brennen WN Graham MK Lotan TL Yates CC De Marzo AM Denmeade SR Yegnasubramanian S Nelson WG Denis GV Platz EA Meeker AK Heaphy CM Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer Nat Rev Urol 2024 21 5 258 73 10.1038/s41585-023-00827-x 37907729
Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian S, Nelson WG, Denis GV, Platz EA, Meeker AK, Heaphy CM. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nat Rev Urol. 2024;21(5):258–73. 10.1038/s41585-023-00827-x.37907729 10.1038/s41585-023-00827-x
100. Passos JF, Miwa S, von Zglinicki T. Measuring reactive oxygen species in senescent cells. Methods Mol Biol., Davalli P, Mitic T, Caporali A, Lauriola A. D’Arca D. ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases. Oxid Med Cell Longev. 2016;2016:3565127. doi: 10.1155/2016/3565127.
101. Aitken RJ, Roman SD. Antioxidant systems and oxidative stress in the testes. Oxid Med Cell Longev. 2008 Oct-Dec;1(1):15–24. 10.4161/oxim.1.1.6843.
102. Donato AJ Machin DR Lesniewski LA Mechanisms of dysfunction in the Aging vasculature and role in Age-Related Disease Circ Res 2018 123 7 825 48 10.1161/CIRCRESAHA.118.312563 30355078
Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction in the Aging vasculature and role in Age-Related Disease. Circ Res. 2018;123(7):825–48. 10.1161/CIRCRESAHA.118.312563.30355078 10.1161/CIRCRESAHA.118.312563
103. Perusquía M Stallone JN Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites Am J Physiol Heart Circ Physiol 2010 298 5 H1301 7 10.1152/ajpheart.00753.2009 20228257
Perusquía M, Stallone JN. Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites. Am J Physiol Heart Circ Physiol. 2010;298(5):H1301–7. 10.1152/ajpheart.00753.2009.20228257 10.1152/ajpheart.00753.2009
104. da Silva FC de Araújo BJ Cordeiro CS Arruda VM Faria BQ Guerra JFDC Araújo TG Fürstenau CR Endothelial dysfunction due to the inhibition of the synthesis of nitric oxide: proposal and characterization of an in vitro cellular model Front Physiol 2022 13 978378 10.3389/fphys.2022.978378 36467706
da Silva FC, de Araújo BJ, Cordeiro CS, Arruda VM, Faria BQ, Guerra JFDC, Araújo TG, Fürstenau CR. Endothelial dysfunction due to the inhibition of the synthesis of nitric oxide: proposal and characterization of an in vitro cellular model. Front Physiol. 2022;13:978378. 10.3389/fphys.2022.978378.36467706 10.3389/fphys.2022.978378
105. Guzik TJ Touyz RM Oxidative stress, inflammation, and vascular aging in hypertension Hypertension 2017 70 4 660 7 10.1161/HYPERTENSIONAHA.117.07802 28784646
Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017;70(4):660–7. 10.1161/HYPERTENSIONAHA.117.07802.28784646 10.1161/HYPERTENSIONAHA.117.07802
106. Phua TJ Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis Front Aging 2023 4 1196648 10.3389/fragi.2023.1196648 37384143
Phua TJ. Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis. Front Aging. 2023;4:1196648. 10.3389/fragi.2023.1196648.37384143 10.3389/fragi.2023.1196648
107. De Marzo AM Platz EA Sutcliffe S Xu J Grönberg H Drake CG Nakai Y Isaacs WB Nelson WG Inflammation in prostate carcinogenesis Nat Rev Cancer 2007 7 4 256 69 10.1038/nrc2090 17384581
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256–69. 10.1038/nrc2090.17384581 10.1038/nrc2090
108. Hsing AW Hormones and prostate cancer: what’s next? Epidemiol Rev 2001 23 1 42 58 10.1093/oxfordjournals.epirev.a000795 11588854
Hsing AW. Hormones and prostate cancer: what’s next? Epidemiol Rev. 2001;23(1):42–58. 10.1093/oxfordjournals.epirev.a000795.11588854 10.1093/oxfordjournals.epirev.a000795
109. Khandrika L Kumar B Koul S Maroni P Koul HK Oxidative stress in prostate cancer Cancer Lett 2009 282 2 125 36 10.1016/j.canlet.2008.12.011 19185987
Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett. 2009;282(2):125–36. 10.1016/j.canlet.2008.12.011.19185987 10.1016/j.canlet.2008.12.011
110. Gupta-Elera G Garrett AR Robison RA O’Neill KL The role of oxidative stress in prostate cancer Eur J Cancer Prev 2012 21 2 155 62 10.1097/CEJ.0b013e32834a8002 21857523
Gupta-Elera G, Garrett AR, Robison RA, O’Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev. 2012;21(2):155–62. 10.1097/CEJ.0b013e32834a8002.21857523 10.1097/CEJ.0b013e32834a8002
111. Han C Wang Z Xu Y Chen S Han Y Li L Wang M Jin X Roles of reactive oxygen species in biological behaviors of prostate Cancer Biomed Res Int 2020 2020 1269624 10.1155/2020/1269624 33062666
Han C, Wang Z, Xu Y, Chen S, Han Y, Li L, Wang M, Jin X. Roles of reactive oxygen species in biological behaviors of prostate Cancer. Biomed Res Int. 2020;2020:1269624. 10.1155/2020/1269624.33062666 10.1155/2020/1269624
112. Wang G Zhao D Spring DJ DePinho RA Genetics and biology of prostate cancer Genes Dev 2018 32 17–18 1105 40 10.1101/gad.315739.118 30181359
Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17–18):1105–40. 10.1101/gad.315739.118.30181359 10.1101/gad.315739.118
113. Webber JP Spary LK Mason MD Tabi Z Brewis IA Clayton A Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes Oncotarget 2016 7 15 20124 39 10.18632/oncotarget.7716 26934553
Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. Oncotarget. 2016;7(15):20124–39. 10.18632/oncotarget.7716.26934553 10.18632/oncotarget.7716
114. Kryza T Silva LM Bock N Fuhrman-Luck RA Stephens CR Gao J Samaratunga H Australian Prostate Cancer BioResourceLawrence MG Hooper JD Dong Y Risbridger GP Clements JA Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells Mol Oncol 2017 11 10 1307 29 10.1002/1878-0261.12075 28510269
Kryza T, Silva LM, Bock N, Fuhrman-Luck RA, Stephens CR, Gao J, Samaratunga H, Australian Prostate Cancer BioResource, Lawrence MG, Hooper JD, Dong Y, Risbridger GP, Clements JA. Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells. Mol Oncol. 2017;11(10):1307–29. 10.1002/1878-0261.12075.28510269 10.1002/1878-0261.12075
115. Tuxhorn JA Ayala GE Smith MJ Smith VC Dang TD Rowley DR Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling Clin Cancer Res 2002 8 9 2912 23 12231536
Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8(9):2912–23.12231536
116. Ni WD Yang ZT Cui CA Cui Y Fang LY Xuan YH Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer Biochem Biophys Res Commun 2017 486 3 607 12 10.1016/j.bbrc.2017.03.021 28341124
Ni WD, Yang ZT, Cui CA, Cui Y, Fang LY, Xuan YH. Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer. Biochem Biophys Res Commun. 2017;486(3):607–12. 10.1016/j.bbrc.2017.03.021.28341124 10.1016/j.bbrc.2017.03.021
117. Ramsay AJ Reid JC Adams MN Samaratunga H Dong Y Clements JA Hooper JD Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs) Biol Chem 2008 389 6 653 68 10.1515/BC.2008.078 18627286
Ramsay AJ, Reid JC, Adams MN, Samaratunga H, Dong Y, Clements JA, Hooper JD. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol Chem. 2008;389(6):653–68. 10.1515/BC.2008.078.18627286 10.1515/BC.2008.078
118. Li Z Li D Tsun A Li B FOXP3 + regulatory T cells and their functional regulation Cell Mol Immunol 2015 12 5 558 65 10.1038/cmi.2015.10 25683611
Li Z, Li D, Tsun A, Li B. FOXP3 + regulatory T cells and their functional regulation. Cell Mol Immunol. 2015;12(5):558–65. 10.1038/cmi.2015.10.25683611 10.1038/cmi.2015.10
119. Xu L Kitani A Strober W Molecular mechanisms regulating TGF-beta-induced Foxp3 expression Mucosal Immunol 2010 3 3 230 8 10.1038/mi.2010.7 20404810
Xu L, Kitani A, Strober W. Molecular mechanisms regulating TGF-beta-induced Foxp3 expression. Mucosal Immunol. 2010;3(3):230–8. 10.1038/mi.2010.7.20404810 10.1038/mi.2010.7
120. Zhang Q Yang XJ Kundu SD Pins M Javonovic B Meyer R Kim SJ Greenberg NM Kuzel T Meagher R Guo Y Lee C Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle Mol Cancer Ther 2006 5 7 1733 43 10.1158/1535-7163.MCT-06-0109 16891459
Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C. Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther. 2006;5(7):1733–43. 10.1158/1535-7163.MCT-06-0109.16891459 10.1158/1535-7163.MCT-06-0109
121. Chiarugi P Paoli P Cirri P Tumor microenvironment and metabolism in prostate cancer Semin Oncol 2014 41 2 267 80 10.1053/j.seminoncol.2014.03.004 24787298
Chiarugi P, Paoli P, Cirri P. Tumor microenvironment and metabolism in prostate cancer. Semin Oncol. 2014;41(2):267–80. 10.1053/j.seminoncol.2014.03.004.24787298 10.1053/j.seminoncol.2014.03.004
122. Thiruvalluvan M Bhowmick NA Stromal-epithelial interactions in Cancer Progression and Therapy Response Cancers (Basel) 2023 15 11 3014 10.3390/cancers15113014 37296976
Thiruvalluvan M, Bhowmick NA. Stromal-epithelial interactions in Cancer Progression and Therapy Response. Cancers (Basel). 2023;15(11):3014. 10.3390/cancers15113014.37296976 10.3390/cancers15113014
123. Levesque C Nelson PS Cellular constituents of the prostate stroma: key contributors to prostate Cancer Progression and Therapy Resistance Cold Spring Harb Perspect Med 2018 8 8 a030510 10.1101/cshperspect.a030510 28490538
Levesque C, Nelson PS. Cellular constituents of the prostate stroma: key contributors to prostate Cancer Progression and Therapy Resistance. Cold Spring Harb Perspect Med. 2018;8(8):a030510. 10.1101/cshperspect.a030510.28490538 10.1101/cshperspect.a030510
124. Li B Wang JH Fibroblasts and myofibroblasts in wound healing: force generation and measurement J Tissue Viability 2011 20 4 108 20 10.1016/j.jtv.2009.11.004 19995679
Li B, Wang JH. Fibroblasts and myofibroblasts in wound healing: force generation and measurement. J Tissue Viability. 2011;20(4):108–20. 10.1016/j.jtv.2009.11.004.19995679 10.1016/j.jtv.2009.11.004
125. Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med., Vickman RE, Kakarla M, Hayward SW, Franco OE. Fibroblast heterogeneity in prostate carcinogenesis. Cancer Lett. 2022;525:76–83. doi: 10.1016/j.canlet.2021.10.028.
126. Owen JS Clayton A Pearson HB Cancer-Associated Fibroblast Heterogeneity, activation and function: implications for prostate Cancer Biomolecules 2022 13 1 67 10.3390/biom13010067 36671452
Owen JS, Clayton A, Pearson HB. Cancer-Associated Fibroblast Heterogeneity, activation and function: implications for prostate Cancer. Biomolecules. 2022;13(1):67. 10.3390/biom13010067.36671452 10.3390/biom13010067
127. Qian Y Feng D Wang J Wei W Wei Q Han P Yang L Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome Sci Rep 2023 13 1 9016 10.1038/s41598-023-36125-0 37270661
Qian Y, Feng D, Wang J, Wei W, Wei Q, Han P, Yang L. Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome. Sci Rep. 2023;13(1):9016. 10.1038/s41598-023-36125-0.37270661 10.1038/s41598-023-36125-0
128. Mishra R Haldar S Suchanti S Bhowmick NA Epigenetic changes in fibroblasts drive cancer metabolism and differentiation Endocr Relat Cancer 2019 26 12 R673 88 10.1530/ERC-19-0347 31627186
Mishra R, Haldar S, Suchanti S, Bhowmick NA. Epigenetic changes in fibroblasts drive cancer metabolism and differentiation. Endocr Relat Cancer. 2019;26(12):R673–88. 10.1530/ERC-19-0347.31627186 10.1530/ERC-19-0347
129. Mishra R Haldar S Placencio V Madhav A Rohena-Rivera K Agarwal P Duong F Angara B Tripathi M Liu Z Gottlieb RA Wagner S Posadas EM Bhowmick NA Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming J Clin Invest 2018 128 10 4472 84 10.1172/JCI99397 30047926
Mishra R, Haldar S, Placencio V, Madhav A, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Tripathi M, Liu Z, Gottlieb RA, Wagner S, Posadas EM, Bhowmick NA. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J Clin Invest. 2018;128(10):4472–84. 10.1172/JCI99397.30047926 10.1172/JCI99397
130. Graham MK, Meeker A. Telomeres and telomerase in prostate cancer Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, Mucci LA, Kenfield SA, Stampfer MJ, Hicks JL, De Marzo AM, Platz EA, Meeker AK. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov. 2013;3(10):1130-41. 10.1158/2159-8290.CD-13-0135
131. Mishra R Haldar S Biondi S Bhari VK Singh G Bhowmick NA TGF-β controls stromal telomere length through epigenetic modifications 3 Biotech 2022 12 11 290 10.1007/s13205-022-03346-5 36276465
Mishra R, Haldar S, Biondi S, Bhari VK, Singh G, Bhowmick NA. TGF-β controls stromal telomere length through epigenetic modifications. 3 Biotech. 2022;12(11):290. 10.1007/s13205-022-03346-5.36276465 10.1007/s13205-022-03346-5
132. Fang Z Xu J Zhang B Wang W Liu J Liang C Hua J Meng Q Yu X Shi S The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives J Hematol Oncol 2020 13 1 154 10.1186/s13045-020-00988-x 33213510
Fang Z, Xu J, Zhang B, Wang W, Liu J, Liang C, Hua J, Meng Q, Yu X, Shi S. The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives. J Hematol Oncol. 2020;13(1):154. 10.1186/s13045-020-00988-x.33213510 10.1186/s13045-020-00988-x
133. Matsuda C Ishii K Nakagawa Y Shirai T Sasaki T Hirokawa YS Iguchi K Watanabe M Fibroblast-derived exosomal microRNA regulates NKX3-1 expression in androgen-sensitive, androgen receptor-dependent prostate cancer cells J Cell Biochem 2023 124 8 1135 44 10.1002/jcb.30435 37334663
Matsuda C, Ishii K, Nakagawa Y, Shirai T, Sasaki T, Hirokawa YS, Iguchi K, Watanabe M. Fibroblast-derived exosomal microRNA regulates NKX3-1 expression in androgen-sensitive, androgen receptor-dependent prostate cancer cells. J Cell Biochem. 2023;124(8):1135–44. 10.1002/jcb.30435.37334663 10.1002/jcb.30435
134. Gandellini P Giannoni E Casamichele A Taddei ML Callari M Piovan C Valdagni R Pierotti MA Zaffaroni N Chiarugi P miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts Antioxid Redox Signal 2014 20 7 1045 59 10.1089/ars.2013.5292 23924028
Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovan C, Valdagni R, Pierotti MA, Zaffaroni N, Chiarugi P. miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid Redox Signal. 2014;20(7):1045–59. 10.1089/ars.2013.5292.23924028 10.1089/ars.2013.5292
135. Peiffer R Boumahd Y Gullo C Crake R Letellier E Bellahcène A Peulen O Cancer-Associated Fibroblast Diversity shapes Tumor Metabolism in Pancreatic Cancer Cancers (Basel) 2022 15 1 61 10.3390/cancers15010061 36612058
Peiffer R, Boumahd Y, Gullo C, Crake R, Letellier E, Bellahcène A, Peulen O. Cancer-Associated Fibroblast Diversity shapes Tumor Metabolism in Pancreatic Cancer. Cancers (Basel). 2022;15(1):61. 10.3390/cancers15010061.36612058 10.3390/cancers15010061
136. Mellone M Hanley CJ Thirdborough S Mellows T Garcia E Woo J Tod J Frampton S Jenei V Moutasim KA Kabir TD Brennan PA Venturi G Ford K Herranz N Lim KP Clarke J Lambert DW Prime SS Underwood TJ Vijayanand P Eliceiri KW Woelk C King EV Gil J Ottensmeier CH Thomas GJ Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis Aging 2016 9 1 114 32 10.18632/aging.101127 27992856
Mellone M, Hanley CJ, Thirdborough S, Mellows T, Garcia E, Woo J, Tod J, Frampton S, Jenei V, Moutasim KA, Kabir TD, Brennan PA, Venturi G, Ford K, Herranz N, Lim KP, Clarke J, Lambert DW, Prime SS, Underwood TJ, Vijayanand P, Eliceiri KW, Woelk C, King EV, Gil J, Ottensmeier CH, Thomas GJ. Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis. Aging. 2016;9(1):114–32. 10.18632/aging.101127.27992856 10.18632/aging.101127
137. Liu H Zhao H Sun Y Tumor microenvironment and cellular senescence: understanding therapeutic resistance and harnessing strategies Semin Cancer Biol 2022 86 Pt 3 769 81 10.1016/j.semcancer.2021.11.004 34799201
Liu H, Zhao H, Sun Y. Tumor microenvironment and cellular senescence: understanding therapeutic resistance and harnessing strategies. Semin Cancer Biol. 2022;86(Pt 3):769–81. 10.1016/j.semcancer.2021.11.004.34799201 10.1016/j.semcancer.2021.11.004
138. Patel GK Chugh N Tripathi M Neuroendocrine differentiation of prostate Cancer-An Intriguing Example of Tumor Evolution at Play Cancers (Basel) 2019 11 10 1405 10.3390/cancers11101405 31547070
Patel GK, Chugh N, Tripathi M. Neuroendocrine differentiation of prostate Cancer-An Intriguing Example of Tumor Evolution at Play. Cancers (Basel). 2019;11(10):1405. 10.3390/cancers11101405.31547070 10.3390/cancers11101405
139. Li Z Sun C Qin Z Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming Theranostics 2021 11 17 8322 36 10.7150/thno.62378 34373744
Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11(17):8322–36. 10.7150/thno.62378.34373744 10.7150/thno.62378
140. Loberg RD Ying C Craig M Yan L Snyder LA Pienta KJ CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration Neoplasia 2007 9 7 556 62 10.1593/neo.07307 17710158
Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007;9(7):556–62. 10.1593/neo.07307.17710158 10.1593/neo.07307
141. Hasegawa H Inoue A Muraoka M Yamanouchi J Miyazaki T Yasukawa M Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4 + CD25 + regulatory T cells in MRL/lpr mice Arthritis Res Ther 2007 9 1 R15 10.1186/ar2122 17284325
Hasegawa H, Inoue A, Muraoka M, Yamanouchi J, Miyazaki T, Yasukawa M. Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4 + CD25 + regulatory T cells in MRL/lpr mice. Arthritis Res Ther. 2007;9(1):R15. 10.1186/ar2122.17284325 10.1186/ar2122
142. Peng L, Shu S, Krauss JC. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res. 1997;57(21):4849-54. PMID: 9354448.
143. Chen IX Chauhan VP Posada J Ng MR Wu MW Adstamongkonkul P Huang P Lindeman N Langer R Jain RK Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer Proc Natl Acad Sci U S A 2019 116 10 4558 66 10.1073/pnas.1815515116 30700545
Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, Huang P, Lindeman N, Langer R, Jain RK. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A. 2019;116(10):4558–66. 10.1073/pnas.1815515116.30700545 10.1073/pnas.1815515116
144. Lazennec G Richmond A Chemokines and chemokine receptors: new insights into cancer-related inflammation Trends Mol Med 2010 16 3 133 44 10.1016/j.molmed.2010.01.003 20163989
Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010;16(3):133–44. 10.1016/j.molmed.2010.01.003.20163989 10.1016/j.molmed.2010.01.003
145. Vickman RE Broman MM Lanman NA Franco OE Sudyanti PAG Ni Y Ji Y Helfand BT Petkewicz J Paterakos MC Crawford SE Ratliff TL Hayward SW Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment Prostate 2020 80 2 173 85 10.1002/pros.23929 31763714
Vickman RE, Broman MM, Lanman NA, Franco OE, Sudyanti PAG, Ni Y, Ji Y, Helfand BT, Petkewicz J, Paterakos MC, Crawford SE, Ratliff TL, Hayward SW. Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. Prostate. 2020;80(2):173–85. 10.1002/pros.23929.31763714 10.1002/pros.23929
146. Xu Y Li W Lin S Liu B Wu P Li L Fibroblast diversity and plasticity in the tumor microenvironment: roles in immunity and relevant therapies Cell Commun Signal 2023 21 1 234 10.1186/s12964-023-01204-2 37723510
Xu Y, Li W, Lin S, Liu B, Wu P, Li L. Fibroblast diversity and plasticity in the tumor microenvironment: roles in immunity and relevant therapies. Cell Commun Signal. 2023;21(1):234. 10.1186/s12964-023-01204-2.37723510 10.1186/s12964-023-01204-2
147. Zhang W Wang J Liu C Li Y Sun C Wu J Wu Q Crosstalk and plasticity driving between cancer-associated fibroblasts and tumor microenvironment: significance of breast cancer metastasis J Transl Med 2023 21 1 827 10.1186/s12967-023-04714-2 37978384
Zhang W, Wang J, Liu C, Li Y, Sun C, Wu J, Wu Q. Crosstalk and plasticity driving between cancer-associated fibroblasts and tumor microenvironment: significance of breast cancer metastasis. J Transl Med. 2023;21(1):827. 10.1186/s12967-023-04714-2.37978384 10.1186/s12967-023-04714-2
148. Luthold C Hallal T Labbé DP Bordeleau F The Extracellular Matrix Stiffening: a trigger of prostate Cancer Progression and Castration Resistance? Cancers (Basel) 2022 14 12 2887 10.3390/cancers14122887 35740556
Luthold C, Hallal T, Labbé DP, Bordeleau F. The Extracellular Matrix Stiffening: a trigger of prostate Cancer Progression and Castration Resistance? Cancers (Basel). 2022;14(12):2887. 10.3390/cancers14122887.35740556 10.3390/cancers14122887
149. Xiong J Xiao R Zhao J Zhao Q Luo M Li F Zhang W Wu M Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy J Transl Med 2024 22 1 85 10.1186/s12967-023-04810-3 38246995
Xiong J, Xiao R, Zhao J, Zhao Q, Luo M, Li F, Zhang W, Wu M. Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy. J Transl Med. 2024;22(1):85. 10.1186/s12967-023-04810-3.38246995 10.1186/s12967-023-04810-3
150. Nguyen EV Pereira BA Lawrence MG Ma X Rebello RJ Chan H Niranjan B Wu Y Ellem S Guan X Wu J Skhinas JN Cox TR Risbridger GP Taylor RA Lister NL Daly RJ Proteomic profiling of human prostate Cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the Tumor Microenvironment Mol Cell Proteom 2019 18 7 1410 27 10.1074/mcp.RA119.001496
Nguyen EV, Pereira BA, Lawrence MG, Ma X, Rebello RJ, Chan H, Niranjan B, Wu Y, Ellem S, Guan X, Wu J, Skhinas JN, Cox TR, Risbridger GP, Taylor RA, Lister NL, Daly RJ. Proteomic profiling of human prostate Cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the Tumor Microenvironment. Mol Cell Proteom. 2019;18(7):1410–27. 10.1074/mcp.RA119.001496.10.1074/mcp.RA119.001496
151. Gong Y Chippada-Venkata UD Oh WK Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression Cancers (Basel) 2014 6 3 1298 327 10.3390/cancers6031298 24978435
Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel). 2014;6(3):1298–327. 10.3390/cancers6031298.24978435 10.3390/cancers6031298
152. Brehmer B Biesterfeld S Jakse G Expression of matrix metalloproteinases (MMP-2 and – 9) and their inhibitors (TIMP-1 and – 2) in prostate cancer tissue Prostate Cancer Prostatic Dis 2003 6 3 217 22 10.1038/sj.pcan.4500657 12970724
Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and – 9) and their inhibitors (TIMP-1 and – 2) in prostate cancer tissue. Prostate Cancer Prostatic Dis. 2003;6(3):217–22. 10.1038/sj.pcan.4500657.12970724 10.1038/sj.pcan.4500657
153. Cui D Li J Zhu Z Berk M Hardaway A McManus J Chung YM Alyamani M Valle S Tiwari R Han B Goudarzi M Willard B Sharifi N Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation J Clin Invest 2023 133 7 e161913 10.1172/JCI161913 37009898
Cui D, Li J, Zhu Z, Berk M, Hardaway A, McManus J, Chung YM, Alyamani M, Valle S, Tiwari R, Han B, Goudarzi M, Willard B, Sharifi N. Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. J Clin Invest. 2023;133(7):e161913. 10.1172/JCI161913.37009898 10.1172/JCI161913
154. Kratochwil C Flechsig P Lindner T Abderrahim L Altmann A Mier W Adeberg S Rathke H Röhrich M Winter H Plinkert PK Marme F Lang M Kauczor HU Jäger D Debus J Haberkorn U Giesel FL 68Ga-FAPI PET/CT: Tracer Uptake in 28 different kinds of Cancer J Nucl Med 2019 60 6 801 5 10.2967/jnumed.119.227967 30954939
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: Tracer Uptake in 28 different kinds of Cancer. J Nucl Med. 2019;60(6):801–5. 10.2967/jnumed.119.227967.30954939 10.2967/jnumed.119.227967
155. Samaržija I The potential of Extracellular Matrix- and integrin adhesion complex-related molecules for prostate Cancer Biomarker Discovery Biomedicines 2023 12 1 79 10.3390/biomedicines12010079 38255186
Samaržija I. The potential of Extracellular Matrix- and integrin adhesion complex-related molecules for prostate Cancer Biomarker Discovery. Biomedicines. 2023;12(1):79. 10.3390/biomedicines12010079.38255186 10.3390/biomedicines12010079
156. Imlimthan S Moon ES Rathke H Afshar-Oromieh A Rösch F Rominger A Gourni E New frontiers in Cancer Imaging and Therapy based on Radiolabeled Fibroblast activation protein inhibitors: a rational review and current progress Pharmaceuticals (Basel) 2021 14 10 1023 10.3390/ph14101023 34681246
Imlimthan S, Moon ES, Rathke H, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E. New frontiers in Cancer Imaging and Therapy based on Radiolabeled Fibroblast activation protein inhibitors: a rational review and current progress. Pharmaceuticals (Basel). 2021;14(10):1023. 10.3390/ph14101023.34681246 10.3390/ph14101023
157. Fendler WP Pabst KM Kessler L Fragoso Costa P Ferdinandus J Weber M Lippert M Lueckerath K Umutlu L Kostbade K Mavroeidi IA Schuler M Ahrens M Rischpler C Bauer S Herrmann K Siveke JT Hamacher R Safety and efficacy of 90Y-FAPI-46 Radioligand Therapy in patients with Advanced Sarcoma and other Cancer entities Clin Cancer Res 2022 28 19 4346 53 10.1158/1078-0432.CCR-22-1432 35833949
Fendler WP, Pabst KM, Kessler L, Fragoso Costa P, Ferdinandus J, Weber M, Lippert M, Lueckerath K, Umutlu L, Kostbade K, Mavroeidi IA, Schuler M, Ahrens M, Rischpler C, Bauer S, Herrmann K, Siveke JT, Hamacher R. Safety and efficacy of 90Y-FAPI-46 Radioligand Therapy in patients with Advanced Sarcoma and other Cancer entities. Clin Cancer Res. 2022;28(19):4346–53. 10.1158/1078-0432.CCR-22-1432.35833949 10.1158/1078-0432.CCR-22-1432
158. Kwak C Jin RJ Lee C Park MS Lee SE Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia BJU Int 2002 89 3 303 9 10.1046/j.1464-4096.2001.01417.x 11856116
Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int. 2002;89(3):303–9. 10.1046/j.1464-4096.2001.01417.x.11856116 10.1046/j.1464-4096.2001.01417.x
159. Belotti D Foglieni C Resovi A Giavazzi R Taraboletti G Targeting angiogenesis with compounds from the extracellular matrix Int J Biochem Cell Biol 2011 43 12 1674 85 10.1016/j.biocel.2011.08.012 21864705
Belotti D, Foglieni C, Resovi A, Giavazzi R, Taraboletti G. Targeting angiogenesis with compounds from the extracellular matrix. Int J Biochem Cell Biol. 2011;43(12):1674–85. 10.1016/j.biocel.2011.08.012.21864705 10.1016/j.biocel.2011.08.012
160. Lawler PR Lawler J Molecular basis for the regulation of angiogenesis by thrombospondin-1 and – 2 Cold Spring Harb Perspect Med 2012 2 5 a006627 10.1101/cshperspect.a006627 22553494
Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and – 2. Cold Spring Harb Perspect Med. 2012;2(5):a006627. 10.1101/cshperspect.a006627.22553494 10.1101/cshperspect.a006627
161. Mongiat M Andreuzzi E Tarticchio G Paulitti A Extracellular matrix, a hard player in Angiogenesis Int J Mol Sci 2016 17 11 1822 10.3390/ijms17111822 27809279
Mongiat M, Andreuzzi E, Tarticchio G, Paulitti A. Extracellular matrix, a hard player in Angiogenesis. Int J Mol Sci. 2016;17(11):1822. 10.3390/ijms17111822.27809279 10.3390/ijms17111822
162. Walker RA The complexities of breast cancer desmoplasia Breast Cancer Res 2001 3 3 143 5 10.1186/bcr287 11305947
Walker RA. The complexities of breast cancer desmoplasia. Breast Cancer Res. 2001;3(3):143–5. 10.1186/bcr287.11305947 10.1186/bcr287
163. DeClerck YA Desmoplasia: a response or a niche? Cancer Discov 2012 2 9 772 4 10.1158/2159-8290.CD-12-0348 22969116
DeClerck YA. Desmoplasia: a response or a niche? Cancer Discov. 2012;2(9):772–4. 10.1158/2159-8290.CD-12-0348.22969116 10.1158/2159-8290.CD-12-0348
164. DeFilippis RA Chang H Dumont N Rabban JT Chen YY Fontenay GV Berman HK Gauthier ML Zhao J Hu D Marx JJ Tjoe JA Ziv E Febbraio M Kerlikowske K Parvin B Tlsty TD CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues Cancer Discov 2012 2 9 826 39 10.1158/2159-8290.CD-12-0107 22777768
DeFilippis RA, Chang H, Dumont N, Rabban JT, Chen YY, Fontenay GV, Berman HK, Gauthier ML, Zhao J, Hu D, Marx JJ, Tjoe JA, Ziv E, Febbraio M, Kerlikowske K, Parvin B, Tlsty TD. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2012;2(9):826–39. 10.1158/2159-8290.CD-12-0107.22777768 10.1158/2159-8290.CD-12-0107
165. Rodriguez-Nieves JA Macoska JA Prostatic fibrosis, lower urinary tract symptoms, and BPH Nat Rev Urol 2013 10 9 546 50 10.1038/nrurol.2013.149 23857178
Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013;10(9):546–50. 10.1038/nrurol.2013.149.23857178 10.1038/nrurol.2013.149
166. Fernandes S Oliver-De La Cruz J Morazzo S Niro F Cassani M Ďuríková H Caravella A Fiore P Azzato G De Marco G Lauria A Izzi V Bosáková V Fric J Filipensky P Forte G TGF-β induces matrisome pathological alterations and EMT in patient-derived prostate cancer tumoroids Matrix Biol 2024 125 12 30 10.1016/j.matbio.2023.11.001 37944712
Fernandes S, Oliver-De La Cruz J, Morazzo S, Niro F, Cassani M, Ďuríková H, Caravella A, Fiore P, Azzato G, De Marco G, Lauria A, Izzi V, Bosáková V, Fric J, Filipensky P, Forte G. TGF-β induces matrisome pathological alterations and EMT in patient-derived prostate cancer tumoroids. Matrix Biol. 2024;125:12–30. 10.1016/j.matbio.2023.11.001.37944712 10.1016/j.matbio.2023.11.001
167. Chandler C Liu T Buckanovich R Coffman LG The double edge sword of fibrosis in cancer Transl Res 2019 209 55 67 10.1016/j.trsl.2019.02.006 30871956
Chandler C, Liu T, Buckanovich R, Coffman LG. The double edge sword of fibrosis in cancer. Transl Res. 2019;209:55–67. 10.1016/j.trsl.2019.02.006.30871956 10.1016/j.trsl.2019.02.006
168. Sato H Hara T Meng S Tsuji Y Arao Y Saito Y Sasaki K Kobayashi S Doki Y Eguchi H Ishii H Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: current understanding and future directions Cancer Sci 2023 114 9 3487 95 10.1111/cas.15890 37480223
Sato H, Hara T, Meng S, Tsuji Y, Arao Y, Saito Y, Sasaki K, Kobayashi S, Doki Y, Eguchi H, Ishii H. Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: current understanding and future directions. Cancer Sci. 2023;114(9):3487–95. 10.1111/cas.15890.37480223 10.1111/cas.15890
169. Wu P Gao W Su M Nice EC Zhang W Lin J Xie N Adaptive mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment Front Cell Dev Biol 2021 9 641469 10.3389/fcell.2021.641469 33732706
Wu P, Gao W, Su M, Nice EC, Zhang W, Lin J, Xie N. Adaptive mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cell Dev Biol. 2021;9:641469. 10.3389/fcell.2021.641469.33732706 10.3389/fcell.2021.641469
170. Guilliams M Ginhoux F Jakubzick C Naik SH Onai N Schraml BU Segura E Tussiwand R Yona S Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny Nat Rev Immunol 2014 14 8 571 8 10.1038/nri3712 25033907
Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, Segura E, Tussiwand R, Yona S. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14(8):571–8. 10.1038/nri3712.25033907 10.1038/nri3712
171. Henry GH Malewska A Joseph DB Malladi VS Lee J Torrealba J Mauck RJ Gahan JC Raj GV Roehrborn CG Hon GC MacConmara MP Reese JC Hutchinson RC Vezina CM Strand DW A Cellular anatomy of the normal adult human prostate and Prostatic Urethra Cell Rep 2018 25 12 3530 e35425 10.1016/j.celrep.2018.11.086 30566875
Henry GH, Malewska A, Joseph DB, Malladi VS, Lee J, Torrealba J, Mauck RJ, Gahan JC, Raj GV, Roehrborn CG, Hon GC, MacConmara MP, Reese JC, Hutchinson RC, Vezina CM, Strand DW. A Cellular anatomy of the normal adult human prostate and Prostatic Urethra. Cell Rep. 2018;25(12):3530–e35425. 10.1016/j.celrep.2018.11.086.30566875 10.1016/j.celrep.2018.11.086
172. Harper J Sainson RC Regulation of the anti-tumour immune response by cancer-associated fibroblasts Semin Cancer Biol 2014 25 69 77 10.1016/j.semcancer.2013.12.005 24406209
Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin Cancer Biol. 2014;25:69–77. 10.1016/j.semcancer.2013.12.005.24406209 10.1016/j.semcancer.2013.12.005
173. Hirz T Mei S Sarkar H Kfoury Y Wu S Verhoeven BM Subtelny AO Zlatev DV Wszolek MW Salari K Murray E Chen F Macosko EZ Wu CL Scadden DT Dahl DM Baryawno N Saylor PJ Kharchenko PV Sykes DB Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses Nat Commun 2023 14 1 663 10.1038/s41467-023-36325-2 36750562
Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, Subtelny AO, Zlatev DV, Wszolek MW, Salari K, Murray E, Chen F, Macosko EZ, Wu CL, Scadden DT, Dahl DM, Baryawno N, Saylor PJ, Kharchenko PV, Sykes DB. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14(1):663. 10.1038/s41467-023-36325-2.36750562 10.1038/s41467-023-36325-2
174. Hu W Qian Y Yu F Liu W Wu Y Fang X Hao W Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma Oncol Lett 2015 10 3 1390 6 10.3892/ol.2015.3400 26622679
Hu W, Qian Y, Yu F, Liu W, Wu Y, Fang X, Hao W. Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma. Oncol Lett. 2015;10(3):1390–6. 10.3892/ol.2015.3400.26622679 10.3892/ol.2015.3400
175. Hellsten R Lilljebjörn L Johansson M Leandersson K Bjartell A The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors Prostate 2019 79 14 1611 21 10.1002/pros.23885 31348843
Hellsten R, Lilljebjörn L, Johansson M, Leandersson K, Bjartell A. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. Prostate. 2019;79(14):1611–21. 10.1002/pros.23885.31348843 10.1002/pros.23885
176. Idorn M Køllgaard T Kongsted P Sengeløv L Thor Straten P Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer Cancer Immunol Immunother 2014 63 11 1177 87 10.1007/s00262-014-1591-2 25085000
Idorn M, Køllgaard T, Kongsted P, Sengeløv L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014;63(11):1177–87. 10.1007/s00262-014-1591-2.25085000 10.1007/s00262-014-1591-2
177. Mhaidly R Mechta-Grigoriou F Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies Semin Immunol 2020 48 101417 10.1016/j.smim.2020.101417 33077325
Mhaidly R, Mechta-Grigoriou F. Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies. Semin Immunol. 2020;48:101417. 10.1016/j.smim.2020.101417.33077325 10.1016/j.smim.2020.101417
178. Palicelli A Bonacini M Croci S Magi-Galluzzi C Cañete-Portillo S Chaux A Bisagni A Zanetti E De Biase D Melli B Sanguedolce F Ragazzi M Bonasoni MP Soriano A Ascani S Zizzo M Castro Ruiz C De Leo A Giordano G Landriscina M Carrieri G Cormio L Berney DM Athanazio D Gandhi J Cavazza A Santandrea G Tafuni A Zanelli M What do we have to know about PD-L1 expression in prostate Cancer? A systematic literature review. Part 1: Focus on Immunohistochemical Results with discussion of pre-analytical and interpretation variables Cells 2021 10 11 3166 10.3390/cells10113166 34831389
Palicelli A, Bonacini M, Croci S, Magi-Galluzzi C, Cañete-Portillo S, Chaux A, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Bonasoni MP, Soriano A, Ascani S, Zizzo M, Castro Ruiz C, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Berney DM, Athanazio D, Gandhi J, Cavazza A, Santandrea G, Tafuni A, Zanelli M. What do we have to know about PD-L1 expression in prostate Cancer? A systematic literature review. Part 1: Focus on Immunohistochemical Results with discussion of pre-analytical and interpretation variables. Cells. 2021;10(11):3166. 10.3390/cells10113166.34831389 10.3390/cells10113166
179. Micke P Strell C Mattsson J Martín-Bernabé A Brunnström H Huvila J Sund M Wärnberg F Ponten F Glimelius B Hrynchyk I Mauchanski S Khelashvili S Garcia-Vicién G Molleví DG Edqvist PH O Reilly A Corvigno S Dahlstrand H Botling J Segersten U Krzyzanowska A Bjartell A Elebro J Heby M Lundgren S Hedner C Borg D Brändstedt J Sartor H Malmström PU Johansson M Nodin B Backman M Lindskog C Jirström K Mezheyeuski A The prognostic impact of the tumour stroma fraction: a machine learning-based analysis in 16 human solid tumour types EBioMedicine 2021 65 103269 10.1016/j.ebiom.2021.103269 33706249
Micke P, Strell C, Mattsson J, Martín-Bernabé A, Brunnström H, Huvila J, Sund M, Wärnberg F, Ponten F, Glimelius B, Hrynchyk I, Mauchanski S, Khelashvili S, Garcia-Vicién G, Molleví DG, Edqvist PH, O Reilly A, Corvigno S, Dahlstrand H, Botling J, Segersten U, Krzyzanowska A, Bjartell A, Elebro J, Heby M, Lundgren S, Hedner C, Borg D, Brändstedt J, Sartor H, Malmström PU, Johansson M, Nodin B, Backman M, Lindskog C, Jirström K, Mezheyeuski A. The prognostic impact of the tumour stroma fraction: a machine learning-based analysis in 16 human solid tumour types. EBioMedicine. 2021;65:103269. 10.1016/j.ebiom.2021.103269.33706249 10.1016/j.ebiom.2021.103269
180. Burrows L Sculthorpe D Zhang H Rehman O Mukherjee A Chen K Mathematical modelling and deep learning algorithms to automate assessment of single and digitally multiplexed immunohistochemical stains in tumoural stroma J Pathol Inf 2023 15 100351 10.1016/j.jpi.2023.100351
Burrows L, Sculthorpe D, Zhang H, Rehman O, Mukherjee A, Chen K. Mathematical modelling and deep learning algorithms to automate assessment of single and digitally multiplexed immunohistochemical stains in tumoural stroma. J Pathol Inf. 2023;15:100351. 10.1016/j.jpi.2023.100351.10.1016/j.jpi.2023.100351
181. Liu F Qi L Liu B Liu J Zhang H Che D Cao J Shen J Geng J Bi Y Ye L Pan B Yu Y Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis PLoS ONE 2015 10 3 e0116683 10.1371/journal.pone.0116683 25775399
Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, Cao J, Shen J, Geng J, Bi Y, Ye L, Pan B, Yu Y. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS ONE. 2015;10(3):e0116683. 10.1371/journal.pone.0116683.25775399 10.1371/journal.pone.0116683
182. An J Hou D Wang L Wang L Yang Y Wang H Fibroblast activation protein-alpha knockdown suppresses prostate cancer cell invasion and proliferation Histol Histopathol 2022 37 6 597 607 10.14670/HH-18-430 35129203
An J, Hou D, Wang L, Wang L, Yang Y, Wang H. Fibroblast activation protein-alpha knockdown suppresses prostate cancer cell invasion and proliferation. Histol Histopathol. 2022;37(6):597–607. 10.14670/HH-18-430.35129203 10.14670/HH-18-430
183. Wu Z Shi J Lai C Li K Li K Li Z Tang Z Liu C Xu K Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients Urol Oncol 2021 39 7 433e 10.1016/j.urolonc.2021.05.004
Wu Z, Shi J, Lai C, Li K, Li K, Li Z, Tang Z, Liu C, Xu K. Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients. Urol Oncol. 2021;39(7):433e. 17-433.e23.10.1016/j.urolonc.2021.05.004
184. Izzi V Davis MN Naba A Pan-cancer Analysis of the genomic alterations and mutations of the Matrisome Cancers (Basel) 2020 12 8 2046 10.3390/cancers12082046 32722287
Izzi V, Davis MN, Naba A. Pan-cancer Analysis of the genomic alterations and mutations of the Matrisome. Cancers (Basel). 2020;12(8):2046. 10.3390/cancers12082046.32722287 10.3390/cancers12082046
185. González LO Eiro N Fraile M Beridze N Escaf AR Escaf S Fernández-Gómez JM Vizoso FJ Prostate Cancer Tumor Stroma: responsibility in Tumor Biology, diagnosis and treatment Cancers (Basel) 2022 14 18 4412 10.3390/cancers14184412 36139572
González LO, Eiro N, Fraile M, Beridze N, Escaf AR, Escaf S, Fernández-Gómez JM, Vizoso FJ. Prostate Cancer Tumor Stroma: responsibility in Tumor Biology, diagnosis and treatment. Cancers (Basel). 2022;14(18):4412. 10.3390/cancers14184412.36139572 10.3390/cancers14184412
186. Xu M Zhang T Xia R Wei Y Wei X Targeting the tumor stroma for cancer therapy Mol Cancer 2022 21 1 208 10.1186/s12943-022-01670-1 36324128
Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer. 2022;21(1):208. 10.1186/s12943-022-01670-1.36324128 10.1186/s12943-022-01670-1
187. Valkenburg KC de Groot AE Pienta KJ Targeting the tumour stroma to improve cancer therapy Nat Rev Clin Oncol 2018 15 6 366 81 10.1038/s41571-018-0007-1 29651130
Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366–81. 10.1038/s41571-018-0007-1.29651130 10.1038/s41571-018-0007-1
188. ClinicalTrials.gov. online database of clinical research studies. https://clinicaltrials.gov/search?cond=Cancer&term=stroma. Accessed 12 April 2024.
189. ClinicalTrials.gov. online database of clinical research studies. https://clinicaltrials.gov/study/NCT04939610?cond=NCT04939610&rank=1. Accessed 12 April 2024.
190. Ochi K Suzawa K Thu YM Takatsu F Tsudaka S Zhu Y Nakata K Takeda T Shien K Yamamoto H Okazaki M Sugimoto S Shien T Okamoto Y Tomida S Toyooka S Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast Cancer Sci 2022 113 10 3428 36 10.1111/cas.15502 35871750
Ochi K, Suzawa K, Thu YM, Takatsu F, Tsudaka S, Zhu Y, Nakata K, Takeda T, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Shien T, Okamoto Y, Tomida S, Toyooka S. Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast. Cancer Sci. 2022;113(10):3428–36. 10.1111/cas.15502.35871750 10.1111/cas.15502
191. Osman S Raza A Al-Zaidan L Inchakalody VP Merhi M Prabhu KS Abdelaziz N Hydrose S Uddin S Dermime S Anti-cancer effects of Tranilast: an update Biomed Pharmacother 2021 141 111844 10.1016/j.biopha.2021.111844 34174504
Osman S, Raza A, Al-Zaidan L, Inchakalody VP, Merhi M, Prabhu KS, Abdelaziz N, Hydrose S, Uddin S, Dermime S. Anti-cancer effects of Tranilast: an update. Biomed Pharmacother. 2021;141:111844. 10.1016/j.biopha.2021.111844.34174504 10.1016/j.biopha.2021.111844
192. Liu Q, Yao F, Wu L, Xu T, Na J, Shen Z, Liu X, Shi W, Zhao Y, Liao Y. Heterogeneity and interplay: the multifaceted role of cancer-associated fibroblasts in the tumor and therapeutic strategies. Clin Transl Oncol. 2024 Apr 11. 10.1007/s12094-024-03492-7. Epub ahead of print.
193. Mediavilla-Varela M Boateng K Noyes D Antonia SJ The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts BMC Cancer 2016 16 176 10.1186/s12885-016-2162-z 26935219
Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer. 2016;16:176. 10.1186/s12885-016-2162-z.26935219 10.1186/s12885-016-2162-z
194. Fujiwara A Funaki S Fukui E Kimura K Kanou T Ose N Minami M Shintani Y Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer Sci Rep 2020 10 1 10900 10.1038/s41598-020-67904-8 32616870
Fujiwara A, Funaki S, Fukui E, Kimura K, Kanou T, Ose N, Minami M, Shintani Y. Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer. Sci Rep. 2020;10(1):10900. 10.1038/s41598-020-67904-8.32616870 10.1038/s41598-020-67904-8
195. Zhang Y Yu R Zhao C Liang J Zhang Y Su H Zhao J Wu H Xu S Zhang Z Wang L Zou X Zhu Y Zhang S Lv Y CAFs homologous biomimetic liposome bearing BET inhibitor and Pirfenidone synergistically promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma Adv Sci (Weinh) 2024 11 1 e2305279 10.1002/advs.202305279 37968249
Zhang Y, Yu R, Zhao C, Liang J, Zhang Y, Su H, Zhao J, Wu H, Xu S, Zhang Z, Wang L, Zou X, Zhu Y, Zhang S, Lv Y. CAFs homologous biomimetic liposome bearing BET inhibitor and Pirfenidone synergistically promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma. Adv Sci (Weinh). 2024;11(1):e2305279. 10.1002/advs.202305279.37968249 10.1002/advs.202305279
196. Bhola NE Balko JM Dugger TC Kuba MG Sánchez V Sanders M Stanford J Cook RS Arteaga CL TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer J Clin Invest 2013 123 3 1348 58 10.1172/JCI65416 23391723
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123(3):1348–58. 10.1172/JCI65416.23391723 10.1172/JCI65416
197. Serova M Tijeras-Raballand A Dos Santos C Albuquerque M Paradis V Neuzillet C Benhadji KA Raymond E Faivre S de Gramont A Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients Oncotarget 2015 6 25 21614 27 10.18632/oncotarget.4308 26057634
Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, Benhadji KA, Raymond E, Faivre S, de Gramont A. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015;6(25):21614–27. 10.18632/oncotarget.4308.26057634 10.18632/oncotarget.4308
198. Joseph JV Balasubramaniyan V Walenkamp A Kruyt FA TGF-β as a therapeutic target in high grade gliomas - promises and challenges Biochem Pharmacol 2013 85 4 478 85 10.1016/j.bcp.2012.11.005 23159669
Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA. TGF-β as a therapeutic target in high grade gliomas - promises and challenges. Biochem Pharmacol. 2013;85(4):478–85. 10.1016/j.bcp.2012.11.005.23159669 10.1016/j.bcp.2012.11.005
199. Tran HC Wan Z Sheard MA Sun J Jackson JR Malvar J Xu Y Wang L Sposto R Kim ES Asgharzadeh S Seeger RC TGFβR1 blockade with Galunisertib (LY2157299) enhances Anti-neuroblastoma Activity of the Anti-GD2 antibody dinutuximab (ch14.18) with natural killer cells Clin Cancer Res 2017 23 3 804 13 10.1158/1078-0432.CCR-16-1743 27756784
Tran HC, Wan Z, Sheard MA, Sun J, Jackson JR, Malvar J, Xu Y, Wang L, Sposto R, Kim ES, Asgharzadeh S, Seeger RC. TGFβR1 blockade with Galunisertib (LY2157299) enhances Anti-neuroblastoma Activity of the Anti-GD2 antibody dinutuximab (ch14.18) with natural killer cells. Clin Cancer Res. 2017;23(3):804–13. 10.1158/1078-0432.CCR-16-1743.27756784 10.1158/1078-0432.CCR-16-1743
200. Ge R Huang GM Targeting transforming growth factor beta signaling in metastatic osteosarcoma J Bone Oncol 2023 43 100513 10.1016/j.jbo.2023.100513 38021074
Ge R, Huang GM. Targeting transforming growth factor beta signaling in metastatic osteosarcoma. J Bone Oncol. 2023;43:100513. 10.1016/j.jbo.2023.100513.38021074 10.1016/j.jbo.2023.100513
